

(19)



(11)

**EP 3 645 532 B9**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**

**Corrections, see**

**Description** Paragraph(s) **67, 73, 74, 75, 76, 77, 78, 104, 111, 112, 115, 119, 143, 148, 150, 152, 153, 197**

**Claims EN 5**

(51) International Patent Classification (IPC):

**C07D 471/04** <sup>(2006.01)</sup>      **C08F 220/18** <sup>(2006.01)</sup>  
**G02C 7/04** <sup>(2006.01)</sup>      **G02B 1/04** <sup>(2006.01)</sup>  
**C08F 230/08** <sup>(2006.01)</sup>      **C08F 271/02** <sup>(2006.01)</sup>  
**C08G 77/20** <sup>(2006.01)</sup>      **C08G 77/26** <sup>(2006.01)</sup>  
**C08J 3/075** <sup>(2006.01)</sup>      **C08L 83/04** <sup>(2006.01)</sup>  
**C08L 83/08** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**31.08.2022 Bulletin 2022/35**

(52) Cooperative Patent Classification (CPC):

(C-Sets available)  
**C07D 471/04; C08F 230/08; C08F 271/02;**  
**C08J 3/075; C08L 83/04; C08L 83/08; G02C 7/04;**  
**C08G 77/20; C08G 77/26; C08J 2383/07 (Cont.)**

(45) Date of publication and mention of the grant of the patent:

**11.05.2022 Bulletin 2022/19**

(86) International application number:

**PCT/IB2018/054588**

(21) Application number: **18746295.7**

(87) International publication number:

**WO 2019/003064 (03.01.2019 Gazette 2019/01)**

(22) Date of filing: **21.06.2018**

**(54) HYDROXYPHENYL PHENANTHROLINES AS POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT FOR PREPARING OPHTHALMIC DEVICES, SUCH AS E.G. CONTACT LENSES**

HYDROXYPHENYL PHENANTHROLINE ALS POLYMERISIERBARE BLOCKER VON HOCHENERGETISCHEM LICHT ZUR HERSTELLUNG VON AUGENMEDIZINISCHEN VORRICHTUNGEN, WIE Z.B. KONTAKTLINSEN

HYDROXYPHÉNYL PHÉNANTHROLINES EN TANT QUE BLOQUANTS DE LUMIÈRE DE HAUT ÉNERGIE POLYMERIZABLES POUR LA PRÉPARATION DE DISPOSITIFS OPHTHALMIQUES, TELS QUE LENTILLES DE CONTACT

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

- **SONODA, Leilani K.**  
Jacksonville, Florida 32256 (US)
- **SINHA, Dola**  
Jacksonville, Florida 32256 (US)
- **MARTIN, Patricia**  
Jacksonville, Florida 32256 (US)

(30) Priority: **30.06.2017 US 201762527109 P**  
**15.05.2018 US 201815979631**

(74) Representative: **Carpmaels & Ransford LLP**  
**One Southampton Row**  
**London WC1B 5HA (GB)**

(43) Date of publication of application:  
**06.05.2020 Bulletin 2020/19**

(73) Proprietor: **Johnson & Johnson Vision Care, Inc.**  
**Jacksonville, FL 32256 (US)**

(56) References cited:  
**EP-A1- 2 123 638**      **WO-A1-2017/073467**  
**US-A1- 2010 168 359**

(72) Inventors:

- **MAHADEVAN, Shivkumar**  
Jacksonville, Florida 32256 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 645 532 B9**

- RECK, LISA M. ET AL: "Enantiopure Chiral Concave 1,10-Phenanthrolines", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2016, no. 6, 2016, pages 1119-1131, XP002784934, ISSN: 1099-0690, DOI: 10.1002/ejoc.201501289
- LAM F ET AL: "Synthesis of Dinucleating Phenanthroline-Based Ligands", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 55, no. 28, 9 July 1999 (1999-07-09), pages 8377-8384, XP004170003, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(99)00428-7
- BERTHON R A ET AL: "SYNTHESIS, ELECTROCHEMICAL AND SPECTROSCOPIC PROPERTIES OF PENDANT HYDROQUINONE- AND QUINONE-SUBSTITUED POLYPYRIDYL RUTHENIUM(II) COMPLEXES", INORGANICA CHIMICA ACTA, ELSEVIER BV, NL, vol. 204, 1993, pages 3-07, XP001062551, ISSN: 0020-1693, DOI: 10.1016/S0020-1693(00)88106-2
- LUENING ULRICH ET AL: "Concave reagents. 5. Bimacrocyclic 1,10-phenanthroline cyclophanes", CHEMISCHE BERI, VCH, DE, vol. 123, no. 3, 1990, pages 643-645, XP008105877, ISSN: 0009-2940, DOI: 10.1002/CBER.19901230335

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

C08F 230/08, C08F 230/08, C08F 220/54, C08F 220/20, C08F 222/102;  
C08F 230/08, C08F 230/08, C08F 220/54, C08F 226/08, C08F 220/20, C08F 220/365, C08F 222/102;  
C08F 271/02, C08F 230/085, C08F 220/54, C08F 220/20, C08F 222/102, C08F 226/06; C08F 283/12, C08F 230/085, C08F 220/54, C08F 220/20, C08F 222/102, C08F 226/10;  
G02B 1/043, C08K 5/0041;  
G02B 1/043, C08L 51/00;  
G02B 1/043, C08L 51/08;  
G02B 1/043, C08L 2666/70

**Description**Field of the Invention

5 **[0001]** The invention relates to high energy light blockers. More particularly, the invention pertains to hydroxyphenyl phenanthroline derivatives with polymerizable functionality that block high energy light (including ultraviolet light) and are visibly transparent when incorporated in an article. Thus, the high energy light blockers may be used in polymeric articles, including biomedical devices, such as ophthalmic devices.

10 Background of the Invention

**[0002]** High energy radiation from the sun, such as UV and high-energy visible light, is known to be responsible for cellular damage. While most of the radiation below 280 nm in wavelength is absorbed by the earth's atmosphere, photons possessing wavelengths ranging between 280 and 400 nm have been associated with several ocular disorders including  
15 corneal degenerative changes, and age related cataract and macular degeneration. (See Statement on Ocular Ultraviolet Radiation Hazards in Sunlight, American Optometric Association, November 10, 1993). The human cornea absorbs radiation up to 320 nm in wavelength (30% transmission) (Doutch, J.J., Quantock, A.J., Joyce, N.C., Meek, K.M, Biophys. J, 2012, 102, 1258-1264), but is inefficient in protecting the back of the eye from radiation ranging from 320 to 400 nm in wavelength.

20 **[0003]** Contact lens standards define the upper UV radiation wavelength at 380 nm. The current Class I UV blocking criteria defined by the American Optometric Association require > 99% of the radiation between 280 and 315 nm (UV B) and > 90% of the 316 to 380 nm (UV A) radiation to be absorbed by the contact lens. While the criteria effectively address protection of the cornea (<1% UV B transmittance), there is little attention paid to the lower energy UV radiation (> 380 < 400 nm) and the high energy visible radiation associated with retinal damage (Ham, W.T, Mueller, H. A., Sliney, D. H. Nature 1976; 260(5547):153-5).

25 **[0004]** Polymerizable compounds possessing appropriate chromophores, if used as ophthalmic device monomers, can help protect the cornea, as well as the interior cells in the ocular environment, from degradation caused by high energy light.

30 **[0005]** WO 2017/073467 A1 discloses a magnesium air battery electrode containing one or more types of metal complex selected from the group consisting of cobalt complexes and iron complexes.

**[0006]** EP 2123638 A1 discloses a metal complex represented by a certain formula said to be useful as a catalyst.

**[0007]** Reck, Lisa M. et al., "Enantiopure Chiral Concave 1,10-Phenanthrolines", European Journal of Organic Chemistry, (2016), vol. 2016, no. 6 discloses axially chiral concave 1,10-phenanthrolines of different sizes synthesized and separated into the corresponding enantiomers.

35 **[0008]** Lam F et al., "Synthesis of Dinucleating Phenanthroline-Based Ligands", Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, (19990709), vol. 55, no. 28 discloses phenolic bridged dinucleating phenanthroline-pyridine, phenanthroline-phosphine, phenanthroline-alcohol, and phenanthroline-imine ligands synthesized from 1,10-phenanthroline via key Stille and Suzuki cross couplings.


40 **[0009]** Berthon R A et al., "Synthesis, Electrochemical And Spectroscopic Properties Of Pendant Hydroquinone- And Quinone-Substitued Polypyridyl Ruthenium(II) Complexes", Inorganica Chimica Acta, Elsevier BV, NL, (1993), vol. 204 discloses parahydroquinonyl-substituted and parabenzoquinonyl-substituted ligands, such as phenanthroline ligands L<sup>1</sup>-L<sup>6</sup>, principally in order to investigate complexes with coordinated hydroquinonyl or quinonyl groups.

**[0010]** Luening Ulrich et al., "Concave reagents. 5. Bimacrocyclic 1,10-phenanthroline cyclophanes", Chemische Ber, VCH, DE, (1990), vol. 123, no. 3 discloses the addition of lithium aryls to 1,10-phenanthroline, functionalization of the rearomatized bisadduct to the tetraphenol, and cyclization of the tetraphenol with two equivalents of an  $\alpha,\omega$ -ditosylate leading to a highly symmetrical, conformer-free bimacrocyclic 1,10-phenanthroline in which the basic and coordinating region possesses a concave shielding.

45 **[0011]** US 2010/168359 A1 discloses tri-functional compounds said to be useful in the production of ophthalmic lenses. The compounds are composed of UV absorber having a polymerization initiator directly or indirectly bonded to the ultraviolet absorber, and an olefinic group directly or indirectly bonded to the ultraviolet absorber.

50 Summary of the Invention

**[0012]** The invention relates to high energy light absorbers with hydroxyphenyl phenanthroline structures having a high absorption (low transmission) over the wavelength range of at least 200-370 nm, while substantially transmitting (e.g., greater than 80% transmission) at wavelengths longer than about 425 nm. The materials are therefore effective at blocking high energy light, such as UV (UVA and UVB) and, in some cases, high energy visible light (e.g., up to 400 nm or greater). In one aspect, therefore, the invention provides a compound of formula I:



Formula I

wherein: R<sup>1</sup> at each occurrence is independently H, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, aryl, or aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl;

at least one R<sup>2</sup> is a group of formula R<sub>g</sub>-L, wherein R<sub>g</sub> is a polymerizable group and L is a linking group, and the remaining R<sup>2</sup> are independently at each occurrence R<sub>g</sub>-L, H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, aryl, or aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl, wherein each alkyl, cycloalkyl, and aryl group is unsubstituted or substituted, wherein R<sub>g</sub> is styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinylamide, (meth)acrylate, or (meth)acrylamide, and

wherein the linking group is C<sub>1</sub>-C<sub>8</sub> alkylene, C<sub>1</sub>-C<sub>8</sub> oxaalkylene, C<sub>1</sub>-C<sub>8</sub> thiaalkylene, C<sub>1</sub>-C<sub>8</sub> alkylene-carboxylate-Ci-Cs alkylene, C<sub>1</sub>-C<sub>8</sub> alkylene-amide-Ci-Cs alkylene, or C<sub>1</sub>-C<sub>8</sub> alkylene-amine-C<sub>1</sub>-C<sub>8</sub> alkylene.

**[0013]** The invention also provides an ophthalmic device comprising the compound of formula I as a free radical reaction product.

**[0014]** The invention further provides a method for making an ophthalmic device. The method comprises: (a) providing a reactive mixture containing a compound of formula I, one or more monomers suitable for use in making an ophthalmic device, and a radical initiator; and (b) polymerizing the reactive mixture to form the ophthalmic device.

**[0015]** The invention also provides a contact lens comprising a hydrogel polymer formed by polymerizing one or more monomers suitable for use in making the hydrogel polymer, and copolymerizing an effective amount of a compound of formula I.

#### Brief Description of Drawings

**[0016]**

FIG. 1 shows transmission spectra of Norbloc<sup>®</sup> and Compound (H) in 0.2 mM methanol solutions.

FIG. 2 shows transmission spectra of contact lenses made in Examples 2A and 2B using Compound H in the reactive monomer mixture.

#### Detailed Description of the Invention

**[0017]** It is to be understood that the invention is not limited to the details of construction or process steps set forth in the following description. The invention is capable of other embodiments and of being practiced or being carried out in various ways using the teaching herein.

**[0018]** As noted above, the invention provides high energy light blockers. The high energy light blockers contain hydroxyphenyl phenanthroline core structures. The materials also contain polymerizable functionality. It has been discovered that such materials are capable of blocking high energy light at over a wide range. For instance, materials according to the invention have been found to comprehensively block high energy light in the wavelength range of at least from 200 to 375 nm, or in the range of 200 to 380 nm, or 200 to 390 nm, or 200 to 400 nm. Advantageously, the materials exhibit a transmission cut-off (e.g., they absorb 20 percent or less, preferably 10 percent or less, more preferably 5% or less) at visible wavelengths longer than about 450 nm or longer than about 425 nm. Thus, the materials successfully block both UVA and UVB while transmitting in the visible spectrum, making them strong Class I and Class II UV absorbers that are well suited for use in ophthalmic applications.

**[0019]** With respect to the terms used in this disclosure, the following definitions are provided.

**[0020]** Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. The polymer definitions are consistent with those disclosed in the Compendium of Polymer Terminology and Nomenclature, IUPAC Recommendations 2008, edited

by: Richard G. Jones, Jaroslav Kahovec, Robert Stepto, Edward S. Wilks, Michael Hess, Tatsuki Kitayama, and W. Val Metanomski.

**[0021]** As used herein, the term "(meth)" designates optional methyl substitution. Thus, a term such as "(meth)acrylates" denotes both methacrylates and acrylates.

**[0022]** Wherever chemical structures are given, it should be appreciated that alternatives disclosed for the substituents on the structure may be combined in any combination. Thus, if a structure contained substituents R\* and R\*\*, each of which contained three lists of potential groups, 9 combinations are disclosed. The same applies for combinations of properties.

**[0023]** When a subscript, such as "n" in the generic formula [\*\*\*]<sub>n</sub>, is used to depict the number of repeating units in a polymer's chemical formula, the formula should be interpreted to represent the number average molecular weight of the macromolecule.

**[0024]** The term "individual" includes humans and vertebrates.

**[0025]** The term "biomedical device" refers to any article that is designed to be used while either in or on mammalian tissues or fluids, and preferably in or on human tissue or fluids. Examples of these devices include but are not limited to wound dressings, sealants, tissue fillers, drug delivery systems, coatings, adhesion prevention barriers, catheters, implants, stents, and ophthalmic devices such as intraocular lenses and contact lenses. The biomedical devices may be ophthalmic devices, particularly contact lenses, most particularly contact lenses made from silicone hydrogels or conventional hydrogels.

**[0026]** The term "ocular surface" includes the surface and glandular epithelia of the cornea, conjunctiva, lacrimal gland, accessory lacrimal glands, nasolacrimal duct and meibomian gland, and their apical and basal matrices, puncta and adjacent or related structures, including eyelids linked as a functional system by both continuity of epithelia, by innervation, and the endocrine and immune systems.

**[0027]** The term "ophthalmic device" refers to any device which resides in or on the eye or any part of the eye, including the ocular surface. These devices can provide optical correction, cosmetic enhancement, vision enhancement, therapeutic benefit (for example as bandages) or delivery of active components such as pharmaceutical and nutraceutical components, or a combination of any of the foregoing. Examples of ophthalmic devices include but are not limited to lenses, optical and ocular inserts, including but not limited to punctal plugs, and the like. "Lenses" include soft contact lenses, hard contact lenses, hybrid contact lenses, intraocular lenses, and overlay lenses. The ophthalmic device may comprise a contact lens.

**[0028]** The term "contact lens" refers to an ophthalmic device that can be placed on the cornea of an individual's eye. The contact lens may provide corrective, cosmetic, or therapeutic benefit, including wound healing, the delivery of drugs or nutraceuticals, diagnostic evaluation or monitoring, ultraviolet light blocking, visible light or glare reduction, or any combination thereof. A contact lens can be of any appropriate material known in the art and can be a soft lens, a hard lens, or a hybrid lens containing at least two distinct portions with different physical, mechanical, or optical properties, such as modulus, water content, light transmission, or combinations thereof.

**[0029]** The biomedical devices, ophthalmic devices, and lenses of the present invention may be comprised of silicone hydrogels or conventional hydrogels. Silicone hydrogels typically contain at least one hydrophilic monomer and at least one silicone-containing component that are covalently bound to one another in the cured device.

**[0030]** "Target macromolecule" means the macromolecule being synthesized from the reactive monomer mixture comprising monomers, macromers, prepolymers, cross-linkers, initiators, additives, diluents, and the like.

**[0031]** The term "polymerizable compound" means a compound containing one or more polymerizable groups. The term encompasses, for instance, monomers, macromers, oligomers, prepolymers, cross-linkers, and the like.

**[0032]** "Polymerizable groups" are groups that can undergo chain growth polymerization, such as free radical and/or cationic polymerization, for example a carbon-carbon double bond which can polymerize when subjected to radical polymerization initiation conditions. Preferably, the free radical polymerizable groups comprise (meth)acrylate, (meth)acrylamide, N-vinyl lactam, N-vinylamide, and styryl functional groups, and mixtures of any of the foregoing. More preferably, the free radical polymerizable groups comprise (meth)acrylates, (meth)acrylamides, and mixtures thereof. The polymerizable group may be unsubstituted or substituted. For instance, the nitrogen atom in (meth)acrylamide may be bonded to a hydrogen, or the hydrogen may be replaced with alkyl or cycloalkyl (which themselves may be further substituted).

**[0033]** Any type of free radical polymerization may be used including but not limited to bulk, solution, suspension, and emulsion as well as any of the controlled radical polymerization methods such as stable free radical polymerization, nitroxide-mediated living polymerization, atom transfer radical polymerization, reversible addition fragmentation chain transfer polymerization, organotellurium mediated living radical polymerization, and the like.

**[0034]** A "monomer" is a mono-functional molecule which can undergo chain growth polymerization, and in particular, free radical polymerization, thereby creating a repeating unit in the chemical structure of the target macromolecule. Some monomers have di-functional impurities that can act as cross-linking agents. A "hydrophilic monomer" is also a monomer which yields a clear single phase solution when mixed with deionized water at 25°C at a concentration of 5 weight percent. A "hydrophilic component" is a monomer, macromer, prepolymer, initiator, cross-linker, additive, or

polymer which yields a clear single phase solution when mixed with deionized water at 25°C at a concentration of 5 weight percent. A "hydrophobic component" is a monomer, macromer, prepolymer, initiator, cross-linker, additive, or polymer which is slightly soluble or insoluble in deionized water at 25°C.

**[0035]** A "macromolecule" is an organic compound having a number average molecular weight of greater than 1500, and may be reactive or non-reactive.

**[0036]** A "macromonomer" or "macromer" is a macromolecule that has one group that can undergo chain growth polymerization, and in particular, free radical polymerization, thereby creating a repeating unit in the chemical structure of the target macromolecule. Typically, the chemical structure of the macromer is different than the chemical structure of the target macromolecule, that is, the repeating unit of the macromer's pendent group is different than the repeating unit of the target macromolecule or its mainchain. The difference between a monomer and a macromer is merely one of chemical structure, molecular weight, and molecular weight distribution of the pendent group. As a result, and as used herein, the patent literature occasionally defines monomers as polymerizable compounds having relatively low molecular weights of about 1,500 Daltons or less, which inherently includes some macromers. In particular, monomethacryloxypropyl terminated mono-n-butyl terminated polydimethylsiloxane (molecular weight = 500-1500 g/mol) (mPDMS) and mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated mono-n-butyl terminated polydimethylsiloxane (molecular weight = 500-1500 g/mol) (OH-mPDMS) may be referred to as monomers or macromers. Furthermore, the patent literature occasionally defines macromers as having one or more polymerizable groups, essentially broadening the common definition of macromer to include prepolymers. As a result, and as used herein, di-functional and multi-functional macromers, prepolymers, and crosslinkers may be used interchangeably.

**[0037]** A "silicone-containing component" is a monomer, macromer, prepolymer, cross-linker, initiator, additive, or polymer in the reactive mixture with at least one silicon-oxygen bond, typically in the form of siloxy groups, siloxane groups, carbosiloxane groups, and mixtures thereof.

**[0038]** Examples of silicone-containing components which are useful in this invention may be found in U.S. Patent Nos. 3,808,178, 4,120,570, 4,136,250, 4,153,641, 4,740,533, 5,034,461, 5,070,215, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,760,100, 5,849,811, 5,962,548, 5,965,631, 5,998,498, 6,367,929, 6,822,016, 6,943,203, 6,951,894, 7,052,131, 7,247,692, 7,396,890, 7,461,937,7,468,398, 7,538,146, 7,553,880, 7,572,841, 7,666,921, 7,691,916, 7,786,185, 7,825,170, 7,915,323, 7,994,356, 8,022,158, 8,163,206, 8,273,802, 8,399,538, 8,415,404, 8,420,711, 8,450,387, 8,487,058, 8,568,626, 8,937,110, 8,937,111, 8,940,812, 8,980,972, 9,056,878, 9,125,808, 9,140,825, 9,156,934, 9,170,349, 9,217,813, 9,244,196, 9,244,197, 9,260,544, 9,297,928, 9,297,929, and European Patent No. 080539. These patents are hereby incorporated by reference in their entireties.

**[0039]** A "polymer" is a target macromolecule composed of the repeating units of the monomers used during polymerization.

**[0040]** A "homopolymer" is a polymer made from one monomer; a "copolymer" is a polymer made from two or more monomers; a "terpolymer" is a polymer made from three monomers. A "block copolymer" is composed of compositionally different blocks or segments. Diblock copolymers have two blocks. Triblock copolymers have three blocks. "Comb or graft copolymers" are made from at least one macromer.

**[0041]** A "repeating unit" is the smallest group of atoms in a polymer that corresponds to the polymerization of a specific monomer or macromer.

**[0042]** An "initiator" is a molecule that can decompose into radicals which can subsequently react with a monomer to initiate a free radical polymerization reaction. A thermal initiator decomposes at a certain rate depending on the temperature; typical examples are azo compounds such as 1,1'-azobisisobutyronitrile and 4,4'-azobis(4-cyanovaleric acid), peroxides such as benzoyl peroxide, tert-butyl peroxide, tert-butyl hydroperoxide, tert-butyl peroxybenzoate, dicumyl peroxide, and lauroyl peroxide, peracids such as peracetic acid and potassium persulfate as well as various redox systems. A photo-initiator decomposes by a photochemical process; typical examples are derivatives of benzil, benzoin, acetophenone, benzophenone, camphorquinone, and mixtures thereof as well as various monoacyl and bisacyl phosphine oxides and combinations thereof.

**[0043]** A "cross-linking agent" is a di-functional or multi-functional monomer or macromer which can undergo free radical polymerization at two or more locations on the molecule, thereby creating branch points and a polymeric network. Common examples are ethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, trimethylolpropane trimethacrylate, methylene bisacrylamide, triallyl cyanurate, and the like.

**[0044]** A "prepolymer" is a reaction product of monomers which contains remaining polymerizable groups capable of undergoing further reaction to form a polymer.

**[0045]** A "polymeric network" is a cross-linked macromolecule that can swell but cannot dissolve in solvents. "Hydrogels" are polymeric networks that swell in water or aqueous solutions, typically absorbing at least 10 weight percent water. "Silicone hydrogels" are hydrogels that are made from at least one silicone-containing component with at least one hydrophilic component. Hydrophilic components may also include non-reactive polymers.

**[0046]** "Conventional hydrogels" refer to polymeric networks made from components without any siloxy, siloxane or carbosiloxane groups. Conventional hydrogels are prepared from reactive mixtures comprising hydrophilic monomers.

Examples include 2-hydroxyethyl methacrylate ("HEMA"), N-vinyl pyrrolidone ("NVP"), N, N-dimethylacrylamide ("DMA") or vinyl acetate. U.S. Patent Nos. 4,436,887, 4,495,313, 4,889,664, 5,006,622, 5,039,459, 5,236,969, 5,270,418, 5,298,533, 5,824,719, 6,420,453, 6,423,761, 6,767,979, 7,934,830, 8,138,290, and 8,389,597 disclose the formation of conventional hydrogels. Commercially available conventional hydrogels include, but are not limited to, etafilcon, genfilcon, hilafilcon, lenefilcon, nesofilcon, omafilcon, polymacon, and vifilcon, including all of their variants.

**[0047]** "Silicone hydrogels" refer to polymeric networks made from at least one hydrophilic component and at least one silicone-containing component. Examples of silicone hydrogels include aquafilcon, asmoofilcon, balafilcon, comfilcon, delefilcon, enfilcon, falcon, fanfilcon, formofilcon, galyfilcon, lotrafilcon, narafilcon, riofilcon, samfilcon, senofilcon, somofilcon, and stenfilcon, including all of their variants, as well as silicone hydrogels as prepared in US Patent Nos. 4,659,782, 4,659,783, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,998,498, 6,087,415, 5,760,100, 5,776,999, 5,789,461, 5,849,811, 5,965,631, 6,367,929, 6,822,016, 6,867,245, 6,943,203, 7,247,692, 7,249,848, 7,553,880, 7,666,921, 7,786,185, 7,956,131, 8,022,158, 8,273,802,8,399,538, 8,470,906, 8,450,387, 8,487,058, 8,507,577, 8,637,621, 8,703,891, 8,937,110, 8,937,111,8,940,812, 9,056,878,9,057,821, 9,125,808,9,140,825,9156,934, 9,170,349, 9,244,196, 9,244,197, 9,260,544, 9,297,928, 9,297,929 as well as WO 03/22321, WO 2008/061992, and US 2010/0048847.

**[0048]** An "interpenetrating polymeric network" comprises two or more networks which are at least partially interlaced on the molecular scale but not covalently bonded to each other and which cannot be separated without breaking chemical bonds. A "semi-interpenetrating polymeric network" comprises one or more networks and one or more polymers characterized by some mixing on the molecular level between at least one network and at least one polymer. A mixture of different polymers is a "polymer blend." A semi-interpenetrating network is technically a polymer blend, but in some cases, the polymers are so entangled that they cannot be readily removed.

**[0049]** The terms "reactive mixture" and "reactive monomer mixture" refer to the mixture of components (both reactive and non-reactive) which are mixed together and when subjected to polymerization conditions form the conventional or silicone hydrogels of the present invention as well as contact lenses made therefrom. The reactive monomer mixture may comprise reactive components such as the monomers, macromers, prepolymers, cross-linkers, and initiators, additives such as wetting agents, release agents, polymers, dyes, light absorbing compounds such as UV absorbers, pigments, dyes and photochromic compounds, any of which may be reactive or non-reactive but are capable of being retained within the resulting biomedical device, as well as pharmaceutical and nutraceutical compounds, and any diluents. It will be appreciated that a wide range of additives may be added based upon the biomedical device which is made and its intended use. Concentrations of components of the reactive mixture are expressed as weight percentages of all components in the reactive mixture, excluding diluent. When diluents are used, their concentrations are expressed as weight percentages based upon the amount of all components in the reactive mixture and the diluent.

**[0050]** "Reactive components" are the components in the reactive mixture which become part of the chemical structure of the polymeric network of the resulting hydrogel by covalent bonding, hydrogen bonding, electrostatic interactions, the formation of interpenetrating polymeric networks, or any other means.

**[0051]** The term "silicone hydrogel contact lens" refers to a hydrogel contact lens comprising at least one silicone containing component. Silicone hydrogel contact lenses generally have increased oxygen permeability compared to conventional hydrogels. Silicone hydrogel contact lenses use both their water and polymer content to transmit oxygen to the eye.

**[0052]** The term "multi-functional" refers to a component having two or more polymerizable groups. The term "mono-functional" refers to a component having one polymerizable group.

**[0053]** The terms "halogen" or "halo" indicate fluorine, chlorine, bromine, and iodine.

**[0054]** As used herein, the term "alkyl" refers to an unsubstituted or substituted linear or branched alkyl group containing the indicated number of carbon atoms. If no number is indicated, then alkyl (optionally including any substituents on alkyl) may contain 1 to 16 carbon atoms. Preferably, the alkyl group contains 1 to 10 carbon atoms, alternatively 1 to 7 carbon atoms, or alternatively 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, propyl, isopropyl, butyl, iso-, sec- and tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, and the like. Examples of substituents on alkyl include 1, 2, or 3 groups independently selected from hydroxy, amino, amido, oxa, carboxy, alkyl carboxy, carbonyl, alkoxy, amido, carbamate, carbonate, halogen, phenyl, benzyl, and combinations thereof. "Alkylene" means a divalent alkyl group, such as  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH(CH_3)CH_2-$ , and  $-CH_2CH_2CH_2CH_2-$ .

**[0055]** "Haloalkyl" refers to an alkyl group as defined above substituted with one or more halogen atoms, where each halogen is independently F, Cl, Br or I. A preferred halogen is F. Preferred haloalkyl groups contain 1-6 carbons, more preferably 1-4 carbons, and still more preferably 1-2 carbons. "Haloalkyl" includes perhaloalkyl groups, such as  $-CF_3-$  or  $-CF_2CF_3-$ . "Haloalkylene" means a divalent haloalkyl group, such as  $-CH_2CF_2-$ .

**[0056]** "Cycloalkyl" refers to an unsubstituted or substituted cyclic hydrocarbon containing the indicated number of ring carbon atoms. If no number is indicated, then cycloalkyl may contain 3 to 12 ring carbon atoms. Preferred are  $C_3$ - $C_8$  cycloalkyl groups,  $C_3$ - $C_7$  cycloalkyl, more preferably  $C_4$ - $C_7$  cycloalkyl, and still more preferably  $C_5$ - $C_6$  cycloalkyl. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Examples of sub-

stituents on cycloalkyl include 1, 2, or 3 groups independently selected from alkyl, hydroxy, amino, amido, oxa, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, and combinations thereof. "Cycloalkylene" means a divalent cycloalkyl group, such as 1,2-cyclohexylene, 1,3-cyclohexylene, or 1,4-cyclohexylene.

**[0057]** "Heterocycloalkyl" refers to a cycloalkyl ring or ring system as defined above in which at least one ring carbon has been replaced with a heteroatom selected from nitrogen, oxygen, and sulfur. The heterocycloalkyl ring is optionally fused to or otherwise attached to other heterocycloalkyl rings and/or non-aromatic hydrocarbon rings and/or phenyl rings. Preferred heterocycloalkyl groups have from 5 to 7 members. More preferred heterocycloalkyl groups have 5 or 6 members. Heterocycloalkylene means a divalent heterocycloalkyl group.

**[0058]** "Aryl" refers to an unsubstituted or substituted aromatic hydrocarbon ring system containing at least one aromatic ring. The aryl group contains the indicated number of ring carbon atoms. If no number is indicated, then aryl may contain 6 to 14 ring carbon atoms. The aromatic ring may optionally be fused or otherwise attached to other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings. Examples of aryl groups include phenyl, naphthyl, and biphenyl. Preferred examples of aryl groups include phenyl. Examples of substituents on aryl include 1, 2, or 3 groups independently selected from alkyl, hydroxy, amino, amido, oxa, carboxy, alkyl carboxy, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, and combinations thereof. "Arylene" means a divalent aryl group, for example 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.

**[0059]** "Heteroaryl" refers to an aryl ring or ring system, as defined above, in which at least one ring carbon atom has been replaced with a heteroatom selected from nitrogen, oxygen, and sulfur. The heteroaryl ring may be fused or otherwise attached to one or more heteroaryl rings, aromatic or nonaromatic hydrocarbon rings or heterocycloalkyl rings. Examples of heteroaryl groups include pyridyl, furyl, and thienyl. "Heteroarylene" means a divalent heteroaryl group.

**[0060]** "Alkoxy" refers to an alkyl group attached to the parent molecular moiety through an oxygen bridge. Examples of alkoxy groups include, for instance, methoxy, ethoxy, propoxy and isopropoxy. "Aryloxy" refers to an aryl group attached to a parent molecular moiety through an oxygen bridge. Examples include phenoxy. "Cyclic alkoxy" means a cycloalkyl group attached to the parent moiety through an oxygen bridge.

**[0061]** "Alkylamine" refers to an alkyl group attached to the parent molecular moiety through an -NH bridge. Alkylamine means a divalent alkylamine group, such as -CH<sub>2</sub>CH<sub>2</sub>NH-.

**[0062]** "Siloxanyl" refers to a structure having at least one Si-O-Si bond. Thus, for example, siloxanyl group means a group having at least one Si-O-Si group (i.e. a siloxane group), and siloxanyl compound means a compound having at least one Si-O-Si group. "Siloxanyl" encompasses monomeric (e.g., Si-O-Si) as well as oligomeric/polymeric structures (e.g., -[Si-O]<sub>n</sub>-, where n is 2 or more). Each silicon atom in the siloxanyl group is substituted with independently selected R<sup>A</sup> groups (where R<sup>A</sup> is as defined in formula A options (b)-(i)) to complete their valence.

**[0063]** "Silyl" refers to a structure of formula R<sub>3</sub>Si- and "siloxyl" refers to a structure of formula R<sub>3</sub>Si-O-, where each R in silyl or siloxyl is independently selected from trimethylsilyloxy, C<sub>1</sub>-C<sub>8</sub> alkyl (preferably C<sub>1</sub>-C<sub>8</sub> alkyl, more preferably ethyl or methyl), and C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

**[0064]** "Alkyleneoxy" refers to groups of the general formula -(alkylene-O)<sub>p</sub>- or -(O-alkylene)<sub>p</sub>-, wherein alkylene is as defined above, and p is from 1 to 200, or from 1 to 100, or from 1 to 50, or from 1 to 25, or from 1 to 20, or from 1 to 10, wherein each alkylene is independently optionally substituted with one or more groups independently selected from hydroxyl, halo (e.g., fluoro), amino, amido, ether, carbonyl, carboxyl, and combinations thereof. If p is greater than 1, then each alkylene may be the same or different and the alkyleneoxy may be in block or random configuration. When alkyleneoxy forms a terminal group in a molecule, the terminal end of the alkyleneoxy may, for instance, be a hydroxy or alkoxy (e.g., HO-[CH<sub>2</sub>CH<sub>2</sub>O]<sub>p</sub>- or CH<sub>3</sub>O-[CH<sub>2</sub>CH<sub>2</sub>O]<sub>p</sub>-). Examples of alkyleneoxy include polymethyleneoxy, polyethyleneoxy, polypropyleneoxy, polybutyleneoxy, and poly(ethyleneoxy-co-propyleneoxy).

**[0065]** "Oxaalkylene" refers to an alkylene group as defined above where one or more non-adjacent CH<sub>2</sub> groups have been substituted with an oxygen atom, such as -CH<sub>2</sub>CH<sub>2</sub>OCH(CH<sub>3</sub>)CH<sub>2</sub>-. "Thiaalkylene" refers to an alkylene group as defined above where one or more non-adjacent CH<sub>2</sub> groups have been substituted with a sulfur atom, such as -CH<sub>2</sub>CH<sub>2</sub>SCH(CH<sub>3</sub>)CH<sub>2</sub>-.

**[0066]** The term "linking group" refers to a moiety that links the polymerizable group to the parent molecule. The linking group may be any moiety that does not undesirably interfere with the polymerization of the compound of which it is a part. The linking group may optionally be substituted with 1 or more substituent groups. Suitable substituent groups may include those independently selected from alkyl, halo (e.g., fluoro), hydroxyl, HO-alkyleneoxy, CH<sub>3</sub>O-alkyleneoxy, siloxanyl, siloxy, siloxy-alkyleneoxy-, siloxy-alkylene-alkyleneoxy- (where more than one alkyleneoxy groups may be present and wherein each methylene in alkylene and alkyleneoxy is independently optionally substituted with hydroxyl), ether, amine, carbonyl, carbamate, and combinations thereof. The linking group may also be substituted with a polymerizable group, such as (meth)acrylate (in addition to the polymerizable group to which the linking group is linked).

**[0067]** Preferred linking groups include C<sub>1</sub>-C<sub>8</sub> alkylene (preferably C<sub>2</sub>-C<sub>6</sub> alkylene) and C<sub>1</sub>-C<sub>8</sub> oxaalkylene (preferably C<sub>2</sub>-C<sub>6</sub> oxaalkylene), each of which is optionally substituted with 1 or 2 groups independently selected from hydroxyl and siloxy. Preferred linking groups also include carboxylate, amide, C<sub>1</sub>-C<sub>8</sub> alkylene-carboxylate-C<sub>1</sub>-C<sub>8</sub> alkylene, or C<sub>1</sub>-C<sub>8</sub> alkylene-amide-C<sub>1</sub>-C<sub>8</sub> alkylene.


**[0068]** When the linking group is comprised of combinations of moieties as described above (e.g., alkylene and cycloalkylene), the moieties may be present in any order. For instance, if in Formula E below, L is indicated as being -alkylene-cycloalkylene-, then R<sub>g</sub>-L may be either R<sub>g</sub>-alkylene-cycloalkylene-, or R<sub>g</sub>-cycloalkylene-alkylene-. Notwithstanding this, the listing order represents the preferred order in which the moieties appear in the compound starting from the terminal polymerizable group (R<sub>g</sub>) to which the linking group is attached. For example, if in Formula E, L and L<sup>2</sup> are indicated as both being alkylene-cycloalkylene-, then R<sub>g</sub>-L is preferably R<sub>g</sub>-alkylene-cycloalkylene- and -L<sup>2</sup>-R<sub>g</sub> is preferably -cycloalkylene-alkylene-R<sub>g</sub>.

**[0069]** The terms "high energy light blocker" or "high energy light absorber" refer to chemical materials which block ultraviolet light and, in some cases, also block high energy visible light. If the amount of a material's blocking is indicated as a percentage for a particular wavelength range, it is to be understood that the material exhibits the percent blocking at all wavelengths within that range. Percent blocking at a particular wavelength can be determined from the material's transmission spectrum, where blocking = 100 - percent transmission (%T). Preferred materials block at least 60%, or at least 70%, or at least 80%, or at least 85%, or at least 90%, or at least 95% of high energy light at all wavelengths within the indicated high energy light range, while significantly transmitting light in the visible range, thus allowing the materials to be used in ophthalmic applications. Preferred materials block 20 % or less, preferably 10 % or less, more preferably 5% or less in the visible spectrum, for instance from 425 nm to 700 nm, or from 450 nm to 700 nm.

**[0070]** Unless otherwise indicated, ratios, percentages, parts, and the like are by weight.

**[0071]** Unless otherwise indicated, numeric ranges, for instance as in "from 2 to 10," are inclusive of the numbers defining the range (e.g., 2 and 10).

**[0072]** As noted above, in one aspect, the invention provides hydroxyphenyl phenanthroline materials that function as high energy light blockers. The hydroxyphenyl phenanthroline materials are of the formula I:



Formula I

wherein: R<sup>1</sup> at each occurrence is independently H, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, aryl, or aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl; at least one R<sup>2</sup> is a group of formula R<sub>g</sub>-L, wherein R<sub>g</sub> is a polymerizable group as defined by claim 1 and L is a linking group as defined by claim 1, and the remaining R<sup>2</sup> are independently at each occurrence R<sub>g</sub>-L, H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, aryl, or aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl, wherein each alkyl, cycloalkyl, and aryl group is unsubstituted or substituted. Hydroxyphenyl phenanthrolines of Formula I preferably contain one or two R<sub>g</sub>-L groups. More preferably, the materials contain one R<sub>g</sub>-L group. The formula I structure (and its various sub-structures as described below) encompasses salts of the hydroxyphenyl phenanthroline compounds (e.g., HCl salts).

**[0073] Formula I-1.** Hydroxyphenyl phenanthrolines of formula I may include materials of formula I-1, which are hydroxyphenyl phenanthrolines of formula I wherein R<sup>1</sup> is independently at each occurrence H or halogen. Preferred materials of formula I-1 include those wherein one R<sup>1</sup> is halo (preferably chloro) and the remaining R<sup>1</sup> are each hydrogen. Preferred materials of formula I-1 also include those wherein each R<sup>1</sup> is hydrogen.


**[0074] I-2.** Hydroxyphenyl phenanthrolines of formulae I and I-1 may include materials of formula I-2, which are hydroxyphenyl phenanthrolines of formula I or I-1 wherein R<sup>2</sup> at each occurrence are independently H, C<sub>1</sub>-C<sub>6</sub> alkyl, or R<sub>g</sub>-L. Preferred materials of formula I-2 include those wherein one R<sup>2</sup> group is R<sub>g</sub>-L and the remaining R<sup>2</sup> groups are independently hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl. Preferred materials of formula I-2 also include those wherein one R<sup>2</sup> is R<sub>g</sub>-L, one R<sup>2</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl (e.g., t-butyl), and the remaining R<sup>2</sup> are each hydrogen. Preferred materials of formula I-2 further include those wherein one R<sup>2</sup> is R<sub>g</sub>-L and the remaining R<sup>2</sup> are each hydrogen.

**[0075] I-3.** Hydroxyphenyl phenanthrolines of formulae I, I-1, and I-2 may include materials of formula I-3, which are hydroxyphenyl phenanthrolines of formula I, I-1, or I-2 wherein R<sub>g</sub> (the polymerizable group) at each occurrence independently comprises styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinylamide, (meth)acrylate, or (meth)acrylamide. The polymerizable group allows the hydroxyphenyl phenanthroline materials of the invention to form covalent bonds when reacted with monomers, crosslinking agents, and other components generally used in making polymeric devices. The compatibility of the hydroxyphenyl phenanthrolines with the reactive mixture can be controlled

via the selection of the polymerizable group (and the linking group). Preferred Rg groups include (meth)acrylate or (meth)acrylamide. A more preferred Rg group is methacrylate.

**[0076] I-4.** Hydroxyphenyl phenanthrolines of formulae I, I-1, I-2, and I-3 may include materials of formula I-4, which are hydroxyphenyl phenanthrolines of formula I, I-1, I-2, or I-3 wherein the linking group comprises C<sub>1</sub>-C<sub>8</sub> alkylene (preferably C<sub>2</sub>-C<sub>6</sub> alkylene), C<sub>1</sub>-C<sub>8</sub> oxaalkylene (preferably C<sub>2</sub>-C<sub>6</sub> oxaalkylene), C<sub>1</sub>-C<sub>8</sub> thiaalkylene (preferably C<sub>2</sub>-C<sub>6</sub> thiaalkylene), C<sub>1</sub>-C<sub>8</sub> alkylene-carboxylate-C<sub>1</sub>-C<sub>8</sub> alkylene, C<sub>1</sub>-C<sub>8</sub> alkylene-amide-C<sub>1</sub>-C<sub>8</sub> alkylene, or C<sub>1</sub>-C<sub>8</sub> alkylene-amine-C<sub>1</sub>-C<sub>8</sub> alkylene. Preferred linking groups may have the structure -[CH<sub>2</sub>]<sub>m</sub>-Y-[CH<sub>2</sub>]<sub>n</sub>-, wherein m is a number from 1 to 6; n is a number from 1 to 6; Y is absent, or is O, S, C(=O)O, NR<sub>5</sub>, or C(=O)NR<sub>5</sub>, wherein R<sub>5</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl. Particularly preferred linking groups are -CH<sub>2</sub>-NH-C(=O)-CH<sub>2</sub>CH<sub>2</sub>- and -CH<sub>2</sub>-O-C(=O)-CH<sub>2</sub>CH<sub>2</sub>-.


**[0077] I-5.** Hydroxyphenyl phenanthrolines of formulae I, I-1, I-2, I-3, and I-4 may include materials of formula I-5, which are hydroxyphenyl phenanthrolines of formula I, I-1, I-2, I-3, or I-4 having the structure:



Formula I-5

wherein the R<sup>2</sup> groups are as defined in formula I or its various sub-formulae (I-1, I-2, I-3, or I-4).

**[0078] I-6.** Hydroxyphenyl phenanthrolines of formulae I, I-1, I-2, I-3, I-4, and I-5 may include materials of formula I-6, which are hydroxyphenyl phenanthrolines of formula I, I-1, I-2, I-3, I-4, or I-5 having the structure:




Formula I-6

wherein the R<sup>2</sup> groups are as defined in formula I or its various sub-formulae (I-1, I-2, I-3, or I-4).

**[0079]** Examples of Hydroxyphenyl phenanthrolines suitable for use in the invention include, but are not limited to, compounds listed in Table 1.


Table 1



2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetoxylethyl methacrylate

(continued)


5



10

2-(2-(4-hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethyl methacrylate


15



20

2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethyl methacrylate

25



30


2-(2-(4-hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethyl methacrylate

35

**[0080]** Compounds of formula I may be prepared as described in the Examples below, as well as relevant literature procedures known to those of skill in the art.

**[0081]** The present invention encompasses compounds that may be used as precursors from which the compounds of formula I may be prepared. These include the following:

40



45

2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetic acid, and salts thereof (e.g., HCl salts).

50

55

**[0082]** As discussed above, the hydroxyphenyl phenanthrolines of formula I are effective at blocking high energy light in at least the 200-375 nm range while transmitting visible wavelengths longer than about 450 nm or longer than about 425 nm. Because of their selective high energy light blocking properties, the compositions are well suited for use in ophthalmic devices. In such devices, the compositions may block harmful high energy radiation, therefore protecting the eye from damage, while allowing transmission of visible light.

**[0083]** The hydroxyphenyl phenanthrolines of formula I may be included in reactive mixtures to form an ophthalmic device. Generally, the hydroxyphenyl phenanthrolines can be present in any amount up to the limit of their solubility.

For instance, the hydroxyphenyl phenanthrolines may be present in an amount in the range of about 0.1 % to about 10 % by weight, or from about 0.5 to about 5% by weight, or from about 0.75% to about 4% by weight. The upper limit is typically determined by the solubility of the compound with other comonomers and or diluents in the reactive monomer mix.

**[0084]** A variety of ophthalmic devices containing the hydroxyphenyl phenanthrolines of the invention may be prepared, including hard contact lenses, soft contact lenses, corneal onlays, corneal inlays, intraocular lenses, or overlay lenses. Preferably, the ophthalmic device is a soft contact lens, which may be made from conventional or silicone hydrogel formulations.

**[0085]** Ophthalmic devices may be prepared by polymerizing a reactive mixture containing the hydroxyphenyl phenanthroline, one or more monomers suitable for making the desired ophthalmic device, and optional components. Thus, the reactive mixture may include, in addition to a hydroxyphenyl phenanthroline compound as described above, one or more of: hydrophilic components, hydrophobic components, silicone-containing components, wetting agents such as polyamides, crosslinking agents, and further components such as diluents and initiators.

### Hydrophilic Components

**[0086]** Examples of suitable families of hydrophilic monomers include (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides, N-vinyl lactams, N-vinyl amides, N-vinyl imides, N-vinyl ureas, O-vinyl carbamates, O-vinyl carbonates, other hydrophilic vinyl compounds, and mixtures thereof.

**[0087]** Non-limiting examples of hydrophilic (meth)acrylate and (meth)acrylamide monomers include: acrylamide, N-isopropyl acrylamide, N,N-dimethylaminopropyl (meth)acrylamide, N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), 2-hydroxypropyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2,3-dihydroxypropyl (meth)acrylate, 2-hydroxybutyl (meth)acrylate, 3-hydroxybutyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate, N-(2-hydroxyethyl) (meth)acrylamide, N,N-bis(2-hydroxyethyl) (meth)acrylamide, N-(2-hydroxypropyl) (meth)acrylamide, N,N-bis(2-hydroxypropyl) (meth)acrylamide, N-(3-hydroxypropyl) (meth)acrylamide, N-(2-hydroxybutyl) (meth)acrylamide, N-(3-hydroxybutyl) (meth)acrylamide, N-(4-hydroxybutyl) (meth)acrylamide, 2-aminoethyl (meth)acrylate, 3-aminopropyl (meth)acrylate, 2-aminopropyl (meth)acrylate, N-2-aminoethyl (meth)acrylamides, N-3-aminopropyl (meth)acrylamide, N-2-aminopropyl (meth)acrylamide, N,N-bis-2-aminoethyl (meth)acrylamides, N,N-bis-3-aminopropyl (meth)acrylamide, N,N-bis-2-aminopropyl (meth)acrylamide, glycerol methacrylate, polyethyleneglycol monomethacrylate, (meth)acrylic acid, vinyl acetate, acrylonitrile, and mixtures thereof.

**[0088]** Hydrophilic monomers may also be ionic, including anionic, cationic, zwitterions, betaines, and mixtures thereof. Non-limiting examples of such charged monomers include (meth)acrylic acid, N-[(ethenoxy)carbonyl]- $\beta$ -alanine (VINAL), 3-acrylamidopropanoic acid (ACA1), 5-acrylamidopentanoic acid (ACA2), 3-acrylamido-3-methylbutanoic acid (AMBA), 2-(methacryloyloxy)ethyl trimethylammonium chloride (Q Salt or METAC), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 1-propanaminium, N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-, inner salt (CBT), 1-propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-, inner salt (SBT), 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide (9CI) (PBT), 2-methacryloyloxyethyl phosphorylcholine, 3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate (DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate (AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate (MAMPDAPS), 3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS), and 3-((3-(methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (MAPDAPS).

**[0089]** Non-limiting examples of hydrophilic N-vinyl lactam and N-vinyl amide monomers include: N-vinyl pyrrolidone (NVP), N-vinyl-2-piperidone, N-vinyl-2-caprolactam, N-vinyl-3-methyl-2-caprolactam, N-vinyl-3-methyl-2-piperidone, N-vinyl-4-methyl-2-piperidone, N-vinyl-4-methyl-2-caprolactam, N-vinyl-3-ethyl-2-pyrrolidone, N-vinyl-4,5-dimethyl-2-pyrrolidone, N-vinyl acetamide (NVA), N-vinyl-N-methylacetamide (VMA), N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl formamide, N-vinyl formamide, N-vinyl-N-methylpropionamide, N-vinyl-N-methyl-2-methylpropionamide, N-vinyl-2-methylpropionamide, N-vinyl-N,N'-dimethylurea, 1-methyl-3-methylene-2-pyrrolidone, 1-methyl-5-methylene-2-pyrrolidone, 5-methyl-3-methylene-2-pyrrolidone; 1-ethyl-5-methylene-2-pyrrolidone, N-methyl-3-methylene-2-pyrrolidone, 5-ethyl-3-methylene-2-pyrrolidone, 1-N-propyl-3-methylene-2-pyrrolidone, 1-N-propyl-5-methylene-2-pyrrolidone, 1-isopropyl-3-methylene-2-pyrrolidone, 1-isopropyl-5-methylene-2-pyrrolidone, N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl formamide, N-vinyl formamide, N-vinyl isopropylamide, N-vinyl caprolactam, N-vinylimidazole, and mixtures thereof

**[0090]** Non-limiting examples of hydrophilic O-vinyl carbamates and O-vinyl carbonates monomers include N-2-hydroxyethyl vinyl carbamate and N-carboxy- $\beta$ -alanine N-vinyl ester. Further examples of hydrophilic vinyl carbonate or vinyl carbamate monomers are disclosed in U.S. Patent No. 5,070,215. Hydrophilic oxazolone monomers are disclosed in U.S. Patent No. 4,910,277.

**[0091]** Other hydrophilic vinyl compounds include ethylene glycol vinyl ether (EGVE), di(ethylene glycol) vinyl ether (DEGVE), allyl alcohol, and 2-ethyl oxazoline.

**[0092]** The hydrophilic monomers may also be macromers or prepolymers of linear or branched poly(ethylene glycol), poly(propylene glycol), or statistically random or block copolymers of ethylene oxide and propylene oxide, having po-

lymerizable moieties such as (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides, N-vinylamides, and the like. The macromers of these polyethers have one polymerizable group; the prepolymers may have two or more polymerizable groups.

[0093] The preferred hydrophilic monomers of the present invention are DMA, NVP, HEMA, VMA, NVA, and mixtures thereof. Other suitable hydrophilic monomers will be apparent to one skilled in the art.

[0094] Generally, there are no particular restrictions with respect to the amount of the hydrophilic monomer present in the reactive monomer mixture. The amount of the hydrophilic monomers may be selected based upon the desired characteristics of the resulting hydrogel, including water content, clarity, wettability, protein uptake, and the like. Wettability may be measured by contact angle, and desirable contact angles are less than about 100°, less than about 80°, and less than about 60°. The hydrophilic monomer may be present in an amount in the range of about 0.1 to about 80 weight percent, including in the range of about 5 to about 65 weight percent, and in the range of about 10 to about 45 weight percent, based on the total weight of the reactive components in the reactive monomer mixture.

#### Silicone-Containing Components


[0095] Silicone-containing components suitable for use in the invention comprise one or more polymerizable compounds, where each compound independently comprises at least one polymerizable group, at least one siloxane group, and one or more linking groups connecting the polymerizable group(s) to the siloxane group(s). The silicone-containing components may, for instance, contain from 1 to 220 siloxane repeat units, such as the groups defined below. The silicone-containing component may also contain at least one fluorine atom.

[0096] The silicone-containing component may comprise: one or more polymerizable groups as defined above; one or more optionally repeating siloxane units; and one or more linking groups connecting the polymerizable groups to the siloxane units. The silicone-containing component may comprise: one or more polymerizable groups that are independently a (meth)acrylate, a styryl, a vinyl ether, a (meth)acrylamide, an N-vinyl lactam, an N-vinylamide, an O-vinylcarbamate, an O-vinylcarbonate, a vinyl group, or mixtures of the foregoing; one or more optionally repeating siloxane units; and one or more linking groups connecting the polymerizable groups to the siloxane units.

[0097] The silicone-containing component may comprise: one or more polymerizable groups that are independently a (meth)acrylate, a (meth)acrylamide, an N-vinyl lactam, an N-vinylamide, a styryl, or mixtures of the foregoing; one or more optionally repeating siloxane units; and one or more linking groups connecting the polymerizable groups to the siloxane units.

[0098] The silicone-containing component may comprise: one or more polymerizable groups that are independently a (meth)acrylate, a (meth)acrylamide, or mixtures of the foregoing; one or more optionally repeating siloxane units; and one or more linking groups connecting the polymerizable groups to the siloxane units.

[0099] **Formula A.** The silicone-containing component may comprise one or more polymerizable compounds of Formula A:



Formula A

wherein:

at least one R<sup>A</sup> is a group of formula R<sub>G</sub>-L- wherein R<sub>G</sub> is a polymerizable group and L is a linking group, and the remaining R<sup>A</sup> are each independently:


- (a) R<sub>G</sub>-L-,
- (b) C<sub>1</sub>-C<sub>16</sub> alkyl optionally substituted with one or more hydroxy, amino, amido, oxa, carboxy, alkyl carboxy, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, or combinations thereof,
- (c) C<sub>3</sub>-C<sub>12</sub> cycloalkyl optionally substituted with one or more alkyl, hydroxy, amino, amido, oxa, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, or combinations thereof,
- (d) a C<sub>6</sub>-C<sub>14</sub> aryl group optionally substituted with one or more alkyl, hydroxy, amino, amido, oxa, carboxy, alkyl carboxy, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, or combinations thereof,

- (e) halo,  
 (f) alkoxy, cyclic alkoxy, or aryloxy,  
 (g) siloxy,  
 (h) alkyleneoxy-alkyl or alkoxy-alkyleneoxy-alkyl, such as polyethyleneoxyalkyl, polypropyleneoxyalkyl, or poly(ethyleneoxy-co-propyleneoxyalkyl), or  
 (i) a monovalent siloxane chain comprising from 1 to 100 siloxane repeat units optionally substituted with alkyl, alkoxy, hydroxy, amino, oxa, carboxy, alkyl carboxy, alkoxy, amido, carbamate, halo or combinations thereof; and

n is from 0 to 500 or from 0 to 200, or from 0 to 100, or from 0 to 20, where it is understood that when n is other than 0, n is a distribution having a mode equal to a stated value. When n is 2 or more, the SiO units may carry the same or different R<sup>A</sup> substituents and if different R<sup>A</sup> substituents are present, the n groups may be in random or block configuration.

**[0100]** In Formula A, three R<sup>A</sup> may each comprise a polymerizable group, alternatively two R<sup>A</sup> may each comprise a polymerizable group, or alternatively one R<sup>A</sup> may comprise a polymerizable group.

**[0101] Formula B.** The silicone-containing component of formula A may be a mono-functional polymerizable compound of formula B:



Formula B

wherein:

R<sub>g</sub> is a polymerizable group;

L is a linking group;

j<sub>1</sub> and j<sub>2</sub> are each independently whole numbers from 0 to 220, provided that the sum of j<sub>1</sub> and j<sub>2</sub> is from 1 to 220;

R<sup>A1</sup>, R<sup>A2</sup>, R<sup>A3</sup>, R<sup>A4</sup>, R<sup>A5</sup> and R<sup>A7</sup> are independently at each occurrence C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>4</sub>-C<sub>12</sub> cyclic alkoxy, alkoxy-alkyleneoxy-alkyl, aryl (e.g., phenyl), aryl-alkyl (e.g., benzyl), haloalkyl (e.g., partially or fully fluorinated alkyl), siloxy, fluoro, or combinations thereof, wherein each alkyl in the foregoing groups is optionally substituted with one or more hydroxy, amino, amido, oxa, carboxy, alkyl carboxy, carbonyl, alkoxy, carbamate, carbonate, halo, phenyl, or benzyl, each cycloalkyl is optionally substituted with one or more alkyl, hydroxy, amino, amido, oxa, carbonyl, alkoxy, carbamate, carbonate, halo, phenyl, or benzyl and each aryl is optionally substituted with one or more alkyl, hydroxy, amino, amido, oxa, carboxy, alkyl carboxy, carbonyl, alkoxy, carbamate, carbonate, halo, phenyl, or benzyl; and

R<sup>A6</sup> is siloxy, C<sub>1</sub>-C<sub>8</sub> alkyl (e.g., C<sub>1</sub>-C<sub>4</sub> alkyl, or butyl, or methyl), or aryl (e.g., phenyl), wherein alkyl and aryl may optionally be substituted with one or more fluorine atoms.

**[0102] Formula B-1.** Compounds of formula B may include compounds of formula B-1, which are compounds of formula B wherein j<sub>1</sub> is zero and j<sub>2</sub> is from 1 to 220, or j<sub>2</sub> is from 1 to 100, or j<sub>2</sub> is from 1 to 50, or j<sub>2</sub> is from 1 to 20, or j<sub>2</sub> is from 1 to 5, or j<sub>2</sub> is 1.

**[0103] B-2.** Compounds of formula B may include compounds of formula B-2, which are compounds of formula B wherein j<sub>1</sub> and j<sub>2</sub> are independently from 4 to 100, or from 4 to 20, or from 4 to 10, or from 24 to 100, or from 10 to 100.

**[0104] B-3.** Compounds of formulae B, B-1, and B-2 may include compounds of formula B-3, which are compounds of formula B, B-1, or B-2 wherein R<sup>A1</sup>, R<sup>A2</sup>, R<sup>A3</sup>, and R<sup>A4</sup> are independently at each occurrence C<sub>1</sub>-C<sub>6</sub> alkyl or siloxy. Preferred alkyl are C<sub>1</sub>-C<sub>3</sub> alkyl, or more preferably, methyl. Preferred siloxy is trimethylsiloxy.

**[0105] B-4.** Compounds of formulae B, B-1, B-2, and B-3 may include compounds of formula B-4, which are compounds of formula B, B-1, B-2, or B-3 wherein R<sup>A5</sup> and R<sup>A7</sup> are independently alkoxy-alkyleneoxy-alkyl, preferably they are independently a methoxy capped polyethyleneoxyalkyl of formula CH<sub>3</sub>O-[CH<sub>2</sub>CH<sub>2</sub>O]<sub>p</sub>-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, wherein p is a whole number from 1 to 50.

**[0106] B-5.** Compounds of formulae B, B-1, B-2, and B-3 may include compounds of formula B-5, which are compounds of formula B, B-1, B-2, or B-3 wherein R<sup>A5</sup> and R<sup>A7</sup> are independently siloxy, such as trimethylsiloxy.

**[0107] B-6.** Compounds of formulae B, B-1, B-2, and B-3 may include compounds of formula B-6, which are compounds of formula B, B-1, B-2, or B-3 wherein  $R^{A5}$  and  $R^{A7}$  are independently  $C_1$ - $C_6$  alkyl, alternatively  $C_1$ - $C_4$  alkyl, or alternatively, butyl or methyl.

**[0108] B-7.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, and B-6 may include compounds of formula B-7, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, or B-6 wherein  $R^{A6}$  is  $C_1$ - $C_8$  alkyl, preferably  $C_1$ - $C_6$  alkyl, more preferably  $C_1$ - $C_4$  alkyl (for example methyl, ethyl, n-propyl, or n-butyl). More preferably  $R^{A6}$  is n-butyl.

**[0109] B-8.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, and B-7, may include compounds of formula B-8, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, or B-7 wherein Rg comprises styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinylamide, (meth)acrylate, or (meth)acrylamide. Preferably, Rg comprises (meth)acrylate, (meth)acrylamide, or styryl. More preferably, Rg comprises (meth)acrylate or (meth)acrylamide. When Rg is (meth)acrylamide, the nitrogen group may be substituted with  $R^{A9}$ , wherein  $R^{A9}$  is H,  $C_1$ - $C_8$  alkyl (preferably  $C_1$ - $C_4$  alkyl, such as n-butyl, n-propyl, methyl or ethyl), or  $C_3$ - $C_8$  cycloalkyl (preferably  $C_5$ - $C_6$  cycloalkyl), wherein alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from hydroxyl, amide, ether, silyl (e.g., trimethylsilyl), siloxy (e.g., trimethylsiloxy), alkyl-siloxanyl (where alkyl is itself optionally substituted with fluoro), aryl-siloxanyl (where aryl is itself optionally substituted with fluoro), and silyl-oxaalkylene- (where the oxaalkylene is itself optionally substituted with hydroxyl).

**[0110] B-9.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, and B-8 may include compounds of formula B-9, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, or B-8 wherein the linking group comprises alkylene (preferably  $C_1$ - $C_4$  alkylene), cycloalkylene (preferably  $C_5$ - $C_6$  cycloalkylene), alkyleneoxy (preferably ethyleneoxy), haloalkyleneoxy (preferably haloethyleneoxy), amide, oxaalkylene (preferably containing 3 to 6 carbon atoms), siloxanyl, alkylsiloxanyl, carbamate, alkyleneamine (preferably  $C_1$ - $C_6$  alkyleneamine), or combinations of two or more thereof, wherein the linking group is optionally substituted with one or more substituents independently selected from alkyl, hydroxyl, ether, amine, carbonyl, siloxy, and carbamate.

**[0111] B-10.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-10, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is alkylene-siloxanyl-alkylene-alkyleneoxy-, or alkylene-siloxanyl-alkylene-[alkyleneoxy-alkylene-siloxanyl]<sub>q</sub>-alkyleneoxy-, where q is from 1 to 50.

**[0112] B-11.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-11, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is  $C_1$ - $C_6$  alkylene, preferably  $C_1$ - $C_3$  alkylene, more preferably n-propylene.

**[0113] B-12.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-12, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is alkylene-carbamate-oxaalkylene. Preferably, the linking group is  $CH_2CH_2N(H)C(=O)OCH_2CH_2OCH_2CH_2CH_2$ .

**[0114] B-13.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-13, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is oxaalkylene. Preferably, the linking group is  $CH_2CH_2OCH_2CH_2CH_2$ .

**[0115] B-14.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-14, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is alkylene-[siloxanyl-alkylene]<sub>q</sub>-, where q is from 1 to 50. An example of such a linking group is:  $-(CH_2)_3-[Si(CH_3)_2O-Si(CH_3)_2-(CH_2)_2]_q-$ .

**[0116] B-15.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-15, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is alkyleneoxy-carbamate-alkylene-cycloalkylene-carbamate-oxaalkylene, wherein cycloalkylene is optionally substituted with or 1, 2, or 3 independently selected alkyl groups (preferably  $C_1$ - $C_3$  alkyl, more preferably methyl). An example of such a linking group is  $-[OCH_2CH_2]_q-OC(=O)-NH-CH_2-[1,3-cyclohexylene]-NHC(=O)O-CH_2CH_2O-CH_2CH_2-$ , wherein the cyclohexylene is substituted at the 1 and 5 positions with 3 methyl groups.

**[0117] B-16.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-16, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein Rg comprises styryl and the linking group is alkyleneoxy wherein each alkylene in alkyleneoxy is independently optionally substituted with hydroxyl. An example of such a linking group is  $-O-(CH_2)_3-$ . Another example of such a linking group is  $-O-CH_2CH(OH)CH_2O-(CH_2)_3-$ .

**[0118] B-17.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-17, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein Rg comprises styryl and the linking group is alkyleneamine. An example of such a linking group is  $-NH-(CH_2)_3-$ .

**[0119] B-18.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-18, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is oxaalkylene optionally substituted with hydroxyl, siloxy, or silyl-alkyleneoxy (where the alkyleneoxy is itself optionally substituted with hydroxyl). An example of such a linking group is  $-CH_2CH(G)CH_2O-(CH_2)_3-$ , wherein G is hydroxyl. In

another example, G is  $R_3SiO-$  wherein two R groups are trimethylsiloxy and the third is  $C_1-C_8$  alkyl (preferably  $C_1-C_3$  alkyl, more preferably methyl) or the third is  $C_3-C_8$  cycloalkyl. In a further example, G is  $R_3Si-(CH_2)_3-O-CH_2CH(OH)CH_2-O-$ , wherein two R groups are trimethylsiloxy and the third is  $C_1-C_8$  alkyl (preferably  $C_1-C_3$  alkyl, more preferably methyl) or  $C_3-C_8$  cycloalkyl. In a still further example, G is a polymerizable group, such as (meth)acrylate.


Such compounds may function as crosslinkers.

**[0120] B-19.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-19, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein  $R_g$  comprises styryl and the linking group is amine-oxaalkylene optionally substituted with hydroxyl. An example of such a linking group is  $-NH-CH_2CH(OH)CH_2-O-(CH_2)_3-$ .

**[0121] B-20.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-20, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein  $R_g$  comprises styryl and the linking group is alkyleneoxy-carbamate-oxaalkylene. An example of such a linking group is  $-O-(CH_2)_2-N(H)C(=O)O-(CH_2)_2-O-(CH_2)_3-$ .

**[0122] B-21.** Compounds of formulae B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, and B-9 may include compounds of formula B-21, which are compounds of formula B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, or B-9 wherein the linking group is alkylene-carbamate-oxaalkylene. An example of such a linking group is  $-(CH_2)_2-N(H)C(=O)O-(CH_2)_2-O-(CH_2)_3-$ .

**[0123] Formula C.** Silicone-containing components of formulae A, B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, B-9, B-10, B-11, B-12, B-13, B-14, B-15, B-18, and B-21 may include compounds of formula C, which are compounds of formula A, B, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, B-9, B-10, B-11, B-12, B-13, B-14, B-15, B-18, or B-21 having the structure:



Formula C

wherein

$R^{A8}$  is hydrogen or methyl;

Z is O, S, or  $N(R^{A9})$ ; and


L,  $j_1$ ,  $j_2$ ,  $R^{A1}$ ,  $R^{A2}$ ,  $R^{A3}$ ,  $R^{A4}$ ,  $R^{A5}$ ,  $R^{A6}$ ,  $R^{A7}$ , and  $R^{A9}$  are as defined in formula B or its various sub-formulae (e.g., B-1, B-2, etc.).

**[0124] C-1.** Compounds of formula C may include (meth)acrylates of formula C-1, which are compounds of formula C wherein Z is O.

**[0125] C-2.** Compounds of formula C may include (meth)acrylamides of formula C-2, which are compounds of formula C wherein Z is  $N(R^{A9})$ , and  $R^{A9}$  is H.

**[0126] C-3.** Compounds of formulae C may include (meth)acrylamides of formula C-3, which are compounds of formula C wherein Z is  $N(R^{A9})$ , and  $R^{A9}$  is  $C_1-C_8$  alkyl that is unsubstituted or is optionally substituted as indicated above. Examples of  $R^{A9}$  include  $CH_3$ ,  $-CH_2CH(OH)CH_2(OH)$ ,  $-(CH_2)_3$ -siloxanyl,  $-(CH_2)_3-SiR_3$ , and  $-CH_2CH(OH)CH_2-O-(CH_2)_3-SiR_3$  where each R in the foregoing groups is independently selected from trimethylsiloxy,  $C_1-C_8$  alkyl (preferably  $C_1-C_3$  alkyl, more preferably methyl), and  $C_3-C_8$  cycloalkyl. Further examples of  $R^{A9}$  include:  $-(CH_2)_3-Si(Me)(SiMe_3)_2$ , and  $-(CH_2)_3-Si(Me_2)-[O-SiMe_2]_{1-10}-CH_3$ .

**[0127] Formula D.** Compounds of formula C may include compounds of formula D:



Formula D

wherein

$R^{A8}$  is hydrogen or methyl;

$Z^1$  is O or  $N(R^{A9})$ ;

$L^1$  is alkylene containing 1 to 8 carbon atoms, or oxaalkylene containing 3 to 10 carbon atoms, wherein  $L^1$  is optionally substituted with hydroxyl; and

$j_2$ ,  $R^{A3}$ ,  $R^{A4}$ ,  $R^{A5}$ ,  $R^{A6}$ ,  $R^{A7}$ , and  $R^{A9}$  are as defined above in formula B or its various sub-formulae (e.g., B-1, B-2, etc.).

**[0128] D-1.** Compounds of formula D may include compounds of formula D-1, which are compounds of formula D wherein  $L^1$  is  $C_2$ - $C_5$  alkylene optionally substituted with hydroxyl. Preferably  $L^1$  is n-propylene optionally substituted with hydroxyl.

**[0129] D-2.** Compounds of formula D may include compounds of formula D-2, which are compounds of formula D wherein  $L^1$  is oxaalkylene containing 4 to 8 carbon atoms optionally substituted with hydroxyl. Preferably  $L^1$  is oxaalkylene containing five or six carbon atoms optionally substituted with hydroxyl. Examples include  $-(CH_2)_2-O-(CH_2)_3-$ , and  $-CH_2CH(OH)CH_2-O-(CH_2)_3-$ .

**[0130] D-3.** Compounds of formulae D, D-1, and D-2 may include compounds of formula D-3, which are compounds of formula D, D-1, or D-2 wherein  $Z^1$  is O.

**[0131] D-4.** Compounds of formulae D, D-1, and D-2 may include compounds of formula D-4, which are compounds of formula D, D-1, or D-2 wherein  $Z^1$  is  $N(R^{A9})$ , and  $R^{A9}$  is H.

**[0132] D-5.** Compounds of formulae D, D-1, and D-2 may include compounds of formula D-5, which are compounds of formula D, D-1, or D-2 wherein  $Z^1$  is  $N(R^{A9})$ , and  $R^{A9}$  is  $C_1$ - $C_4$  alkyl optionally substituted with 1 or 2 substituents selected from hydroxyl, siloxy, and  $C_1$ - $C_6$  alkyl-siloxanyl-.


**[0133] D-6.** Compounds of formulae D, D-1, D-2, D-3, D-4, and D-5 may include compounds of formula D-6, which are compounds of formula D, D-1, D-2, D-3, D-4, or D-5 wherein  $j_2$  is 1.

**[0134] D-7.** Compounds of formulae D, D-1, D-2, D-3, D-4, and D-5 may include compounds of formula D-7, which are compounds of formula D, D-1, D-2, D-3, D-4, or D-5 wherein  $j_2$  is from 2 to 220, or from 2 to 100, or from 10 to 100, or from 24 to 100, or from 4 to 20, or from 4 to 10.

**[0135] D-8.** Compounds of formulae D, D-1, D-2, D-3, D-4, D-5, D-6, and D-7 may include compounds of formula D-8, which are compounds of formula D, D-1, D-2, D-3, D-4, D-5, D-6, or D-7 wherein  $R^{A3}$ ,  $R^{A4}$ ,  $R^{A5}$ ,  $R^{A6}$ , and  $R^{A7}$  are independently  $C_1$ - $C_6$  alkyl or siloxy. Preferably  $R^{A3}$ ,  $R^{A4}$ ,  $R^{A5}$ ,  $R^{A6}$ , and  $R^{A7}$  are independently selected from methyl, ethyl, n-propyl, n-butyl, and trimethylsiloxy. More preferably,  $R^{A3}$ ,  $R^{A4}$ ,  $R^{A5}$ ,  $R^{A6}$ , and  $R^{A7}$  are independently selected from methyl, n-butyl, and trimethylsiloxy.

**[0136] D-9.** Compounds of formulae D, D-1, D-2, D-3, D-4, D-5, D-6, and D-7 may include compounds of formula D-9, which are compounds of formula D, D-1, D-2, D-3, D-4, D-5, D-6, or D-7 wherein  $R^{A3}$  and  $R^{A4}$  are independently  $C_1$ - $C_6$  alkyl (e.g., methyl or ethyl) or siloxy (e.g., trimethylsiloxy), and  $R^{A5}$ ,  $R^{A6}$ , and  $R^{A7}$  are independently  $C_1$ - $C_6$  alkyl (e.g., methyl, ethyl, n-propyl, or n-butyl).

**[0137] Formula E.** The silicone-containing component for use in the invention may comprise a multi-functional silicone-containing component. Thus, for example, the silicone-containing component of formula A may comprise a bifunctional material of formula E:



Formula E

wherein

R<sub>g</sub>, L, j<sub>1</sub>, j<sub>2</sub>, R<sup>A1</sup>, R<sup>A2</sup>, R<sup>A3</sup>, R<sup>A4</sup>, R<sup>A5</sup>, and R<sup>A7</sup> are as defined above for formula B or its various sub-formulae (e.g., B-1, B-2, etc.);

L<sup>2</sup> is a linking group; and

R<sub>g</sub><sup>1</sup> is a polymerizable group.

**[0138] E-1.** Compounds of formula E may include compounds of formula E-1, which are compounds of formula E wherein R<sub>g</sub> and R<sub>g</sub><sup>1</sup> are each a vinyl carbonate of structure CH<sub>2</sub>=CHO-C(=O)-O- or structure CH<sub>2</sub>=C(CH<sub>3</sub>)-O-C(=O)-O-.

**[0139] E-2.** Compounds of formula E may include compounds of formula E-2, which are compounds of formula E wherein R<sub>g</sub> and R<sub>g</sub><sup>1</sup> are each (meth)acrylate.

**[0140] E-3.** Compounds of formula E may include compounds of formula E-3, which are compounds of formula E wherein R<sub>g</sub> and R<sub>g</sub><sup>1</sup> are each (meth)acrylamide, wherein the nitrogen group may be substituted with R<sup>A9</sup> (wherein R<sup>A9</sup> is as defined above).

**[0141] E-4.** Suitable compounds of formulae E, E-1, E-2, and E-3 include compounds of formula E-4, which are compounds of formula E, E-1, E-2, or E-3 wherein j<sub>1</sub> is zero and j<sub>2</sub> is from 1 to 220, or j<sub>2</sub> is from 1 to 100, or j<sub>2</sub> is from 1 to 50, or j<sub>2</sub> is from 1 to 20.

**[0142] E-5.** Suitable compounds of formulae E, E-1, E-2, and E-3 include compounds of formula E-5, which are compounds of formula E, E-1, E-2, or E-3, wherein j<sub>1</sub> and j<sub>2</sub> are independently from 4 to 100.

**[0143] E-6.** Suitable compounds of formulae E, E-1, E-2, E-3, E-4, and E-5 include compounds of formula E-6, which are compounds of formula E, E-1, E-2, E-3, E-4, or E-5 wherein R<sup>A1</sup>, R<sup>A2</sup>, R<sup>A3</sup>, R<sup>A4</sup>, and R<sup>A5</sup> are independently at each occurrence C<sub>1</sub>-C<sub>6</sub> alkyl, preferably they are independently C<sub>1</sub>-C<sub>3</sub> alkyl, or preferably, each is methyl.

**[0144] E-7.** Suitable compounds of formulae E, E-1, E-2, E-3, E-4, E-5, and E-6 include compounds of formula E-7, which are compounds of formula E, E-1, E-2, E-3, E-4, E-5, or E-6 wherein R<sup>A7</sup> is alkoxy-alkyleneoxy-alkyl, preferably it is a methoxy capped polyethyleneoxyalkyl of formula CH<sub>3</sub>O-[CH<sub>2</sub>CH<sub>2</sub>O]<sub>p</sub>-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, wherein p is a whole number from 1 to 50, or from 1 to 30, or from 1 to 10, or from 6 to 10.

**[0145] E-8.** Suitable compounds of formulae E, E-1, E-2, E-3, E-4, E-5, E-6, and E-7 include compounds of formula E-8, which are compounds of formula E, E-1, E-2, E-3, E-4, E-5, E-6, or E-7 wherein L comprises alkylene, carbamate, siloxanyl, cycloalkylene, amide, haloalkyleneoxy, oxaalkylene, or combinations of two or more thereof, wherein the linking group is optionally substituted with one or more substituents independently selected from alkyl, hydroxyl, ether, amine, carbonyl, and carbamate.

**[0146] E-9.** Suitable compounds of formulae E, E-1, E-2, E-3, E-4, E-5, E-6, E-7, and E-8 include compounds of formula E-9, which are compounds of formula E, E-1, E-2, E-3, E-4, E-5, E-6, E-7, or E-8 wherein L<sup>2</sup> comprises alkylene, carbamate, siloxanyl, cycloalkylene, amide, haloalkyleneoxy, oxaalkylene, or combinations of two or more thereof, wherein the linking group is optionally substituted with one or more substituents independently selected from alkyl, hydroxyl, ether, amine, carbonyl, and carbamate.

**[0147]** Examples of silicone-containing components suitable for use in the invention include, but are not limited to, compounds listed in Table 3. Where the compounds in Table 3 contain polysiloxane groups, the number of SiO repeat units in such compounds, unless otherwise indicated, is preferably from 3 to 100, more preferably from 3 to 40, or still more preferably from 3 to 20.


Table 3

1	mono-methacryloxypropyl terminated mono-n-butyl terminated polydimethylsiloxanes (mPDMS) (preferably containing from 3 to 15 SiO repeating units)
2	mono-acryloxypropyl terminated mono-n-butyl terminated polydimethylsiloxane
3	mono(meth)acryloxypropyl terminated mono-n-methyl terminated polydimethylsiloxane

(continued)


4	mono(meth)acryloxypropyl terminated mono-n-butyl terminated polydiethylsiloxane
5	mono(meth)acryloxypropyl terminated mono-n-methyl terminated polydiethylsiloxane
6	mono(meth)acrylamidoalkylpolydialkylsiloxanes
7	mono(meth)acryloxyalkyl terminated mono-alkyl polydiarylsiloxanes
8	3-methacryloxypropyltris(trimethylsiloxy)silane (TRIS)
9	3-methacryloxypropylbis(trimethylsiloxy)methylsilane
10	3-methacryloxypropylpentamethyl disiloxane
11	mono(meth)acrylamidoalkylpolydialkylsiloxanes
12	mono(meth)acrylamidoalkyl polydimethylsiloxanes
13	N-(2,3-dihydroxypropane)-N'-(propyl tetra(dimethylsiloxy) dimethylbutylsilane)acrylamide
14	N-[3-tris(trimethylsiloxy)silyl]-propyl acrylamide (TRIS-Am)
15	2-hydroxy-3-[3-methyl-3,3-di(trimethylsiloxy)silylpropoxy]-propyl methacrylate (SiMAA)
16	2-hydroxy-3-methacryloxypropyloxypropyl-tris(trimethylsiloxy)silane
17	mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated mono-n-butyl terminated polydimethylsiloxanes (OH-mPDMS) (containing from 4 to 30, or from 10 to 20, or from 4 to 8 SiO repeat units)
18	
19	
20	
21	
22	

(continued)



20 **[0148]** Additional non-limiting examples of suitable silicone-containing components are listed in Table 4. Unless otherwise indicated,  $j_2$  where applicable is preferably from 1 to 100, more preferably from 3 to 40, or still more preferably from 3 to 15. In compounds containing  $j_1$  and  $j_2$ , the sum of  $j_1$  and  $j_2$  is preferably from 2 to 100, more preferably from 3 to 40, or still more preferably from 3 to 15.


Table 4



(continued)

5	28	
10	29	
15	30	1,3-bis[4-(vinylloxycarbonyloxy)but-1-yl]tetramethyl-disiloxane
15	31	3-(vinylloxycarbonylthio) propyl-[tris(trimethylsiloxy)silane]
15	32	3-[tris(trimethylsiloxy)silyl] propyl allyl carbamate
15	33	3-[tris(trimethylsiloxy)silyl] propyl vinyl carbamate
20	34	tris(trimethylsiloxy)silylstyrene (Styryl-TRIS)
25	35	<p> <math>R^A = \text{CH}_3</math> (a) or <math>\text{CH}_2\text{CH}_2\text{CF}_3</math> (b) or <math>\text{CH}_2-(\text{CH}_2)_2-</math>  <math>[\text{OCH}_2\text{CH}_2]_{1-10}-\text{OCH}_3</math> (c); <math>a + b + c = n</math> </p>
30	36	
35	37	
40	38	
45	39	
50	39	
55		

(continued)



20 **[0149]** Silicone-containing components for use in the invention may have an average molecular weight of from about 400 to about 4000 daltons.

**[0150]** The silicone containing component(s) may be present in amounts up to about 95 weight %, or from about 10 to about 80 weight %, or from about 20 to about 70 weight %, based upon all reactive components of the reactive mixture (excluding diluents).


25

#### Polyamides

30 **[0151]** The reactive monomer mixture may include at least one polyamide. As used herein, the term "polyamide" refers to polymers and copolymers comprising repeating units containing amide groups. The polyamide may comprise cyclic amide groups, acyclic amide groups and combinations thereof and may be any polyamide known to those of skill in the art. Acyclic polyamides comprise pendant acyclic amide groups and are capable of association with hydroxyl groups. Cyclic polyamides comprise cyclic amide groups and are capable of association with hydroxyl groups.

**[0152]** Examples of suitable acyclic polyamides include polymers and copolymers comprising repeating units of Formulae G1 and G2:


35



Formula G1

50

55




Formula G2

15 wherein X is a direct bond,  $-(CO)-$ , or  $-(CONHR_{44})-$ , wherein  $R_{44}$  is a  $C_1$  to  $C_3$  alkyl group;  $R_{40}$  is selected from H, straight or branched, substituted or unsubstituted  $C_1$  to  $C_4$  alkyl groups;  $R_{41}$  is selected from H, straight or branched, substituted or unsubstituted  $C_1$  to  $C_4$  alkyl groups, amino groups having up to two carbon atoms, amide groups having up to four carbon atoms, and alkoxy groups having up to two carbon atoms;  $R_{42}$  is selected from H, straight or branched, substituted or unsubstituted  $C_1$  to  $C_4$  alkyl groups; or methyl, ethoxy, hydroxyethyl, and hydroxymethyl;  $R_{43}$  is selected from H, straight or branched, substituted or unsubstituted  $C_1$  to  $C_4$  alkyl groups; or methyl, ethoxy, hydroxyethyl, and hydroxymethyl; wherein the number of carbon atoms in  $R_{40}$  and  $R_{41}$  taken together is 8 or less, including 7, 6, 5, 4, 3, or less; and wherein the number of carbon atoms in  $R_{42}$  and  $R_{43}$  taken together is 8 or less, including 7, 6, 5, 4, 3, or less. The number of carbon atoms in  $R_{40}$  and  $R_{41}$  taken together may be 6 or less or 4 or less. The number of carbon atoms in  $R_{42}$  and  $R_{43}$  taken together may be 6 or less. As used herein substituted alkyl groups include alkyl groups substituted with an amine, amide, ether, hydroxyl, carbonyl or carboxy groups or combinations thereof.


20  
25 **[0153]**  $R_{40}$  and  $R_{41}$  may be independently selected from H, substituted or unsubstituted  $C_1$  to  $C_2$  alkyl groups. X may be a direct bond, and  $R_{40}$  and  $R_{41}$  may be independently selected from H, substituted or unsubstituted  $C_1$  to  $C_2$  alkyl groups.  $R_{42}$  and  $R_{43}$  can be independently selected from H, substituted or unsubstituted  $C_1$  to  $C_2$  alkyl groups, methyl, ethoxy, hydroxyethyl, and hydroxymethyl.

30 **[0154]** The acyclic polyamides of the present invention may comprise a majority of the repeating units of Formula LV or Formula LVI, or the acyclic polyamides can comprise at least 50 mole percent of the repeating unit of Formula G or Formula G1, including at least 70 mole percent, and at least 80 mole percent. Specific examples of repeating units of Formula G and Formula G1 include repeating units derived from N-vinyl-N-methylacetamide, N-vinylacetamide, N-vinyl-N-methylpropionamide, N-vinyl-N-methyl-2-methylpropionamide, N-vinyl-2-methylpropionamide, N-vinyl-N,N'-dimethylurea, N, N-dimethylacrylamide, methacrylamide, and acyclic amides of Formulae G2 and G3:

35




Formula G2



Formula G3

55 **[0155]** Examples of suitable cyclic amides that can be used to form the cyclic polyamides of include  $\alpha$ -lactam,  $\beta$ -lactam,

$\gamma$ -lactam,  $\delta$ -lactam, and  $\epsilon$ -lactam. Examples of suitable cyclic polyamides include polymers and copolymers comprising repeating units of Formula G4:



Formula G4

wherein  $R_{45}$  is a hydrogen atom or methyl group; wherein  $f$  is a number from 1 to 10; wherein  $X$  is a direct bond,  $-(CO)-$ , or  $-(CONHR_{46})-$ , wherein  $R_{46}$  is a  $C_1$  to  $C_3$  alkyl group. In Formula LIX,  $f$  may be 8 or less, including 7, 6, 5, 4, 3, 2, or 1. In Formula G4,  $f$  may be 6 or less, including 5, 4, 3, 2, or 1. In Formula G4,  $f$  may be from 2 to 8, including 2, 3, 4, 5, 6, 7, or 8. In Formula LIX,  $f$  may be 2 or 3. When  $X$  is a direct bond,  $f$  may be 2. In such instances, the cyclic polyamide may be polyvinylpyrrolidone (PVP).

**[0156]** The cyclic polyamides of the present invention may comprise 50 mole percent or more of the repeating unit of Formula G4, or the cyclic polyamides can comprise at least 50 mole percent of the repeating unit of Formula G4, including at least 70 mole percent, and at least 80 mole percent.

**[0157]** The polyamides may also be copolymers comprising repeating units of both cyclic and acyclic amides. Additional repeating units may be formed from monomers selected from hydroxyalkyl(meth)acrylates, alkyl(meth)acrylates, other hydrophilic monomers and siloxane substituted (meth)acrylates. Any of the monomers listed as suitable hydrophilic monomers may be used as comonomers to form the additional repeating units. Specific examples of additional monomers which may be used to form polyamides include 2-hydroxyethyl (meth)acrylate, vinyl acetate, acrylonitrile, hydroxypropyl (meth)acrylate, methyl (meth)acrylate and hydroxybutyl (meth)acrylate, dihydroxypropyl (meth)acrylate, polyethylene glycol mono(meth)acrylate, and the like and mixtures thereof. Ionic monomers may also be included. Examples of ionic monomers include (meth)acrylic acid,  $N$ -[(ethenoxy)carbonyl]- $\beta$ -alanine (VINAL, CAS #148969-96-4), 3-acrylamidopropanoic acid (ACA1), 5-acrylamidopentanoic acid (ACA2), 3-acrylamido-3-methylbutanoic acid (AMBA), 2-(methacryloyloxy)ethyl trimethylammonium chloride (Q Salt or METAC), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 1-propanaminium,  $N$ -(2-carboxyethyl)- $N,N$ -dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-, inner salt (CBT, carboxybetaine; CAS 79704-35-1), 1-propanaminium,  $N,N$ -dimethyl- $N$ -[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-, inner salt (SBT, sulfobetaine, CAS 80293-60-3), 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium, 4-hydroxy- $N,N,N$ -trimethyl-9-oxo-, inner salt, 4-oxide (9CI) (PBT, phosphobetaine, CAS 163674-35-9, 2-methacryloyloxyethyl phosphorylcholine, 3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate (DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate (AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate (MAMPDAPS), 3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS), 3-((3-(methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (MAPDAPS).

**[0158]** The reactive monomer mixture may comprise both an acyclic polyamide and a cyclic polyamide or copolymers thereof. The acyclic polyamide can be any of those acyclic polyamides described herein or copolymers thereof, and the cyclic polyamide can be any of those cyclic polyamides described herein or copolymers thereof. The polyamide may be selected from the group polyvinylpyrrolidone (PVP), polyvinylmethylacetamide (PVMA), polydimethylacrylamide (PDMA), polyvinylacetamide (PNVA), poly hydroxyethyl (meth)acrylamide, polyacrylamide, and copolymers and mixtures thereof.

**[0159]** The total amount of all polyamides in the reactive mixture may be in the range of between 1 weight percent and about 35 weight percent, including in the range of about 1 weight percent to about 15 weight percent, and in the range of about 5 weight percent to about 15 weight percent, in all cases, based on the total weight of the reactive components of the reactive monomer mixture.

**[0160]** Without intending to be bound by theory, when used with a silicone hydrogel, the polyamide functions as an internal wetting agent. The polyamides of the present invention may be non-polymerizable, and in this case, are incorporated into the silicone hydrogels as semi-interpenetrating networks. The polyamides are entrapped or physically retained within the silicone hydrogels. Alternatively, the polyamides of the present invention may be polymerizable, for example as polyamide macromers or prepolymers, and in this case, are covalently incorporated into the silicone hydrogels. Mixtures of polymerizable and non-polymerizable polyamides may also be used.

**[0161]** When the polyamides are incorporated into the reactive monomer mixture they may have a weight average molecular weight of at least 100,000 daltons; greater than about 150,000; between about 150,000 to about 2,000,000 daltons; between about 300,000 to about 1,800,000 daltons. Higher molecular weight polyamides may be used if they are compatible with the reactive monomer mixture.

#### Cross-linking Agents

**[0162]** It is generally desirable to add one or more cross-linking agents, also referred to as cross-linking monomers, multi-functional macromers, and prepolymers, to the reactive mixture. The cross-linking agents may be selected from bifunctional crosslinkers, trifunctional crosslinkers, tetrafunctional crosslinkers, and mixtures thereof, including silicone-containing and non-silicone containing cross-linking agents. Non-silicone-containing cross-linking agents include ethylene glycol dimethacrylate (EGDMA), tetraethylene glycol dimethacrylate (TEGDMA), trimethylolpropane trimethacrylate (TMPTMA), triallyl cyanurate (TAC), glycerol trimethacrylate, methacryloxyethyl vinylcarbonate (HEMAVc), allyl methacrylate, methylene bisacrylamide (MBA), and polyethylene glycol dimethacrylate wherein the polyethylene glycol has a molecular weight up to about 5000 Daltons. The cross-linking agents are used in the usual amounts, e.g., from about 0.000415 to about 0.0156 mole per 100 grams of reactive Formulas in the reactive mixture. Alternatively, if the hydrophilic monomers and/or the silicone-containing components are multifunctional by molecular design or because of impurities, the addition of a cross-linking agent to the reactive mixture is optional. Examples of hydrophilic monomers and macromers which can act as the cross-linking agents and when present do not require the addition of an additional cross-linking agent to the reactive mixture include (meth)acrylate and (meth)acrylamide endcapped polyethers. Other cross-linking agents will be known to one skilled in the art and may be used to make the silicone hydrogel of the present invention.

**[0163]** It may be desirable to select crosslinking agents with similar reactivity to one or more of the other reactive components in the formulation. In some cases, it may be desirable to select a mixture of crosslinking agents with different reactivity in order to control some physical, mechanical or biological property of the resulting silicone hydrogel. The structure and morphology of the silicone hydrogel may also be influenced by the diluent(s) and cure conditions used.

**[0164]** Multifunctional silicone-containing components, including macromers, cross-linking agents, and prepolymers, may also be included to further increase the modulus and retain tensile strength. The silicone containing cross-linking agents may be used alone or in combination with other cross-linking agents. An example of a silicone containing component which can act as a cross-linking agent and, when present, does not require the addition of a crosslinking monomer to the reactive mixture includes  $\alpha$ ,  $\omega$ -bismethacryloxypropyl polydimethylsiloxane.

**[0165]** Cross-linking agents that have rigid chemical structures and polymerizable groups that undergo free radical polymerization may also be used. Non-limiting examples of suitable rigid structures include cross-linking agents comprising phenyl and benzyl moieties, such as 1,4-phenylene diacrylate, 1,4-phenylene dimethacrylate, 2,2-bis(4-methacryloxyphenyl)propane, 2,2-bis[4-(2-acryloxyethoxy)phenyl]propane, 2,2-bis[4-(2-hydroxy-3-methacryloxypropoxy)phenyl]propane, and 4-vinylbenzyl methacrylate, and combinations thereof. Rigid crosslinking agents may be included in amounts between about 0.5 and about 15, or 2-10, 3-7 based upon the total weight of all of the reactive components. The physical and mechanical properties of the silicone hydrogels of the present invention may be optimized for a particular use by adjusting the components in the reactive mixture.

**[0166]** Non-limiting examples of silicone cross-linking agents also include the multi-functional silicone-containing components described above, such as compounds of Formula E (and its sub-formulae) and the multi-functional compounds shown in Table 3.

#### Further Constituents

**[0167]** The reactive monomer mixture may contain additional components such as, but not limited to, diluents, initiators, UV absorbers, visible light absorbers, photochromic compounds, pharmaceuticals, nutraceuticals, antimicrobial substances, tints, pigments, copolymerizable dyes, nonpolymerizable dyes, release agents, and combinations thereof.

**[0168]** Classes of suitable diluents for silicone hydrogel reactive mixtures include alcohols having 2 to 20 carbon atoms, amides having 10 to 20 carbon atoms derived from primary amines and carboxylic acids having 8 to 20 carbon atoms. The diluents may be primary, secondary, and tertiary alcohols.

**[0169]** Generally, the reactive components are mixed in a diluent to form a reactive mixture. Suitable diluents are known in the art. For silicone hydrogels, suitable diluents are disclosed in WO 03/022321 and US6020445.

Classes of suitable diluents for silicone hydrogel reactive mixtures include alcohols having 2 to 20 carbons, amides having 10 to 20 carbon atoms derived from primary amines, and carboxylic acids having 8 to 20 carbon atoms. Primary and tertiary alcohols may be used. Preferred classes include alcohols having 5 to 20 carbons and carboxylic acids having 10 to 20 carbon atoms. Specific diluents which may be used include 1-ethoxy-2-propanol, diisopropyl aminoethanol, isopropanol, 3,7-dimethyl-3-octanol, 1-decanol, 1-dodecanol, 1-octanol, 1-pentanol, 2-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 3-methyl-3-pentanol, tert-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-propanol,

1-propanol, ethanol, 2-ethyl-1-butanol, (3-acetoxy-2-hydroxypropyloxy)-propylbis(trimethylsiloxy) methylsilane, 1-tert-butoxy-2-propanol, 3,3-dimethyl-2-butanol, tert-butoxyethanol, 2-octyl-1-dodecanol, decanoic acid, octanoic acid, dodecanoic acid, 2-(diisopropylamino)ethanol mixtures thereof and the like. Examples of amide diluents include N,N-dimethyl propionamide and dimethyl acetamide.

5 **[0170]** Preferred diluents include 3,7-dimethyl-3-octanol, 1-dodecanol, 1-decanol, 1-octanol, 1-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 3-methyl-3-pentanol, 2-pentanol, t-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-ethyl-1-butanol, ethanol, 3,3-dimethyl-2-butanol, 2-octyl-1-dodecanol, decanoic acid, octanoic acid, dodecanoic acid, mixtures thereof and the like.

10 **[0171]** More preferred diluents include 3,7-dimethyl-3-octanol, 1-dodecanol, 1-decanol, 1-octanol, 1-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 1-dodecanol, 3-methyl-3-pentanol, 1-pentanol, 2-pentanol, t-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-ethyl-1-butanol, 3,3-dimethyl-2-butanol, 2-octyl-1-dodecanol, mixtures thereof and the like. If a diluent is present, generally there are no particular restrictions with respect to the amount of diluent present. When diluent is used, the diluent may be present in an amount in the range of about 2 to about 70 weight percent, including in the range of about 5 to about 50 weight percent, and in the range of about 15 to about 40 weight percent, based on the total weight of the reactive mixtures (including reactive and nonreactive Formulas). Mixtures of diluents may be used.

15 **[0172]** A polymerization initiator may be used in the reactive mixture. The polymerization initiator may include, for instance, at least one of lauroyl peroxide, benzoyl peroxide, iso-propyl percarbonate, azobisisobutyronitrile, and the like, that generate free radicals at moderately elevated temperatures, and photoinitiator systems such as aromatic alpha-hydroxy ketones, alkoxyoxybenzoin, acetophenones, acylphosphine oxides, bisacylphosphine oxides, and a tertiary amine plus an  $\alpha$ -diketone, mixtures thereof and the like. Illustrative examples of photoinitiators are 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methyl-1-phenyl-propan-1-one, bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentyl phosphine oxide (DMBAPO), bis(2,4,6-trimethylbenzoyl)-phenyl phosphine oxide (Irgacure 819), 2,4,6-trimethylbenzoyldiphenyl phosphine oxide and 2,4,6-trimethylbenzoyl diphenylphosphine oxide, benzoin methyl ester and a combination of camphorquinone and ethyl 4-(N,N-dimethylamino)benzoate. Diazo thermal initiators may also be used, such as azobisisobutyronitrile (AIBN), 2,2'-azobis(2-methylbutyronitrile) (AMBN) or similar compounds.

20 **[0173]** Commercially available visible light initiator systems include Irgacure<sup>®</sup> 819, Irgacure<sup>®</sup> 1700, Irgacure<sup>®</sup> 1800, Irgacure<sup>®</sup> 819, Irgacure<sup>®</sup> 1850 (all from Ciba Specialty Chemicals) and Lucrin<sup>®</sup> TPO initiator (available from BASF). Commercially available UV photoinitiators include Darocur<sup>®</sup> 1173 and Darocur<sup>®</sup> 2959 (Ciba Specialty Chemicals). These and other photoinitiators which may be used are disclosed in Volume III, Photoinitiators for Free Radical Cationic & Anionic Photopolymerization, 2nd Edition by J. V. Crivello & K. Dietliker; edited by G. Bradley; John Wiley and Sons; New York; 1998. The initiator is used in the reactive mixture in effective amounts to initiate photopolymerization of the reactive mixture, e.g., from about 0.1 to about 2 parts by weight per 100 parts of reactive monomer mixture. Polymerization of the reactive mixture can be initiated using the appropriate choice of heat or visible or ultraviolet light or other means depending on the polymerization initiator used. Alternatively, initiation can be conducted using e-beam without a photoinitiator. However, when a photoinitiator is used, the preferred initiators are bisacylphosphine oxides, such as bis(2,4,6-trimethylbenzoyl)-phenyl phosphine oxide (Irgacure<sup>®</sup> 819) or a combination of 1-hydroxycyclohexyl phenyl ketone and bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentyl phosphine oxide (DMBAPO).

25 **[0174]** The reactive mixture for making the ophthalmic devices of the invention may comprise, in addition to a hydroxyphenyl phenanthroline of formula I, any of the polymerizable compounds and optional components described above.

30 **[0175]** Preferred reactive mixtures may comprise: a hydroxyphenyl phenanthroline of formula I and a hydrophilic monomer.

35 **[0176]** Preferred reactive mixtures may comprise: a hydroxyphenyl phenanthroline of formula I; and a hydrophilic monomer selected from DMA, NVP, HEMA, VMA, NVA, methacrylic acid, and mixtures thereof. Preferred are mixtures of HEMA and methacrylic acid.

40 **[0177]** Preferred reactive mixtures may comprise: a hydroxyphenyl phenanthroline of formula I, a hydrophilic monomer, and a silicone-containing component.

45 **[0178]** Preferred reactive mixtures may comprise: a hydroxyphenyl phenanthroline of formula I, a hydrophilic monomer, and a silicone-containing component comprising a compound of formula D (or its sub-formulae, such as D-1, D-2, etc.).

50 **[0179]** Preferred reactive mixtures may comprise: a hydroxyphenyl phenanthroline of formula I, a hydrophilic monomer selected from DMA, NVP, HEMA, VMA, NVA, and mixtures thereof; a silicone-containing component comprising a compound of formula D (or its sub-formulae, such as D-1, D-2, etc.); and an internal wetting agent.

55 **[0180]** Preferred reactive mixtures may comprise: a hydroxyphenyl phenanthroline of formula I, a hydrophilic monomer selected from DMA, HEMA and mixtures thereof; a silicone-containing component selected from 2-hydroxy-3-[3-methyl-3,3-di(trimethylsiloxy)silylpropoxy]-propyl methacrylate (SiMAA), mono-methacryloxypropyl terminated mono-n-butyl terminated polydimethylsiloxane (mPDMS), mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated mono-n-butyl terminated polydimethylsiloxane (OH-mPDMS), and mixtures thereof; and a wetting agent (preferably PVP or PVMA). For the hydrophilic monomer, mixtures of DMA and HEMA are preferred. For the silicone containing component,

mixtures of SiMAA and mPDMS are preferred.

**[0181]** The foregoing reactive mixtures may contain optional ingredients such as, but not limited to, one or more initiators, internal wetting agents, crosslinkers, other UV blockers, and diluents.

#### 5 Curing of Hydrogels and Manufacture of Lens

**[0182]** The reactive mixtures may be formed by any of the methods known in the art, such as shaking or stirring, and used to form polymeric articles or devices by known methods. The reactive components are mixed together either with or without a diluent to form the reactive mixture.

10 **[0183]** For example, hydrogels may be prepared by mixing reactive components, and, optionally, diluent(s), with a polymerization initiator and curing by appropriate conditions to form a product that can be subsequently formed into the appropriate shape by lathing, cutting, and the like. Alternatively, the reactive mixture may be placed in a mold and subsequently cured into the appropriate article.

15 **[0184]** A method of making a silicone hydrogel contact lens may comprise: preparing a reactive monomer mixture; transferring the reactive monomer mixture onto a first mold; placing a second mold on top the first mold filled with the reactive monomer mixture; and curing the reactive monomer mixture by free radical copolymerization to form the silicone hydrogel in the shape of a contact lens.

20 **[0185]** The reactive mixture may be cured via any known process for molding the reactive mixture in the production of contact lenses, including spincasting and static casting. Spincasting methods are disclosed in U.S. Patents Nos. 3,408,429 and 3,660,545, and static casting methods are disclosed in U.S. Patents Nos. 4,113,224 and 4,197,266. The contact lenses of this invention may be formed by the direct molding of the silicone hydrogels, which is economical, and enables precise control over the final shape of the hydrated lens. For this method, the reactive mixture is placed in a mold having the shape of the final desired silicone hydrogel and the reactive mixture is subjected to conditions whereby the monomers polymerize, thereby producing a polymer in the approximate shape of the final desired product.

25 **[0186]** After curing, the lens may be subjected to extraction to remove unreacted components and release the lens from the lens mold. The extraction may be done using conventional extraction fluids, such organic solvents, such as alcohols or may be extracted using aqueous solutions.

30 **[0187]** Aqueous solutions are solutions which comprise water. The aqueous solutions of the present invention may comprise at least about 20 weight percent water, or at least about 50 weight percent water, or at least about 70 weight percent water, or at least about 95 weight percent water. Aqueous solutions may also include additional water soluble components such as inorganic salts or release agents, wetting agents, slip agents, pharmaceutical and nutraceutical compounds, combinations thereof and the like. Release agents are compounds or mixtures of compounds which, when combined with water, decrease the time required to release a contact lens from a mold, as compared to the time required to release such a lens using an aqueous solution that does not comprise the release agent. The aqueous solutions may not require special handling, such as purification, recycling or special disposal procedures.

35 **[0188]** Extraction may be accomplished, for example, via immersion of the lens in an aqueous solution or exposing the lens to a flow of an aqueous solution. Extraction may also include, for example, one or more of: heating the aqueous solution; stirring the aqueous solution; increasing the level of release aid in the aqueous solution to a level sufficient to cause release of the lens; mechanical or ultrasonic agitation of the lens; and incorporating at least one leaching or extraction aid in the aqueous solution to a level sufficient to facilitate adequate removal of unreacted components from the lens. The foregoing may be conducted in batch or continuous processes, with or without the addition of heat, agitation or both.

40 **[0189]** Application of physical agitation may be desired to facilitate leach and release. For example, the lens mold part to which a lens is adhered can be vibrated or caused to move back and forth within an aqueous solution. Other methods may include ultrasonic waves through the aqueous solution.

45 **[0190]** The lenses may be sterilized by known means such as, but not limited to, autoclaving.

50 **[0191]** The hydroxyphenyl phenanthroline compositions of the invention may absorb UV radiation over a wavelength range comprising 200-375 nm, preferably comprising 200-380 nm, while transmitting wavelengths longer than about 450 nm or longer than about 425 nm. Within the 200-375 nm or 200-380 nm ranges, the hydroxyphenyl phenanthroline compositions, when incorporated in a hydrogel lens, may block 70%, 80%, 85%, 90%, or 95% of the radiation. For instance, in a UV transmittance spectrum of a conventional or silicone hydrogel lens containing the hydroxyphenyl phenanthroline composition of the invention at a concentration of about 0.6 mol % and having a center thickness of at least about 73 microns, the maximum transmittance of radiation within the indicated wavelength range may be up to 30%, alternatively up to 20%, alternatively up to 15%, alternatively up to 10% or alternatively up to 5%. Exemplary procedures for measuring transmittance are described below.

55 **[0192]** Silicone hydrogel ophthalmic devices (e.g., contact lenses) according to the invention preferably have the following properties. All values are prefaced by "about," and the devices may have any combination of the listed properties. The properties may be determined by methods known to those skilled in the art, for instance as described in United

States pre-grant publication US20180037690.

[H<sub>2</sub>O] %: at least 20 %, or at least 25 %  
 Haze: 30 % or less, or 10 % or less  
 5 Kruss DCA (°): 100° or less, or 50° or less  
 Tensile Modulus (psi): 120 or less, or 80 to 120  
 Dk (barrers): at least 80, or at least 100, or at least 150, or at least 200  
 Elongation to Break: at least 100

10 **[0193]** For ionic silicon hydrogels, the following properties may also be preferred (in addition to those recited above):

Lysozyme uptake (μg/lens): at least 100, or at least 150, or at least 500, or at least 700  
 Polyquatonium 1 (PQ1) uptake (%): 15 or less, or 10 or less, or 5 or less  
 15 Some embodiments of the invention will now be described in detail in the following Examples.

UV-VIS Test Methods

20 **[0194]** Ultraviolet-visible spectra of organic compounds in solution were measured on a Perkin Elmer Lambda 45 or an Agilent Cary 6000i UV/VIS scanning spectrometer. The instrument was thermally equilibrated for at least thirty minutes prior to use. For the Perkin Elmer instrument, the scan range was 200-800 nm; the scan speed was 960 nm per minute; the slit width was 4 nm; the mode was set on transmission or absorbance; and baseline correction was selected. For the Cary instrument, the scan range was 200-800 nm; the scan speed was 600 nm/min; the slit width was 2 nm; the mode was transmission or absorbance; and baseline correction was selected. A baseline correction was performed before samples were analyzed using the autozero function.

25 **[0195]** Ultraviolet-visible spectra of contact lenses were measured on a Perkin Elmer Lambda 45 UV/VIS or an Agilent Cary 6000i UV/VIS scanning spectrometer using packing solution. The instrument was thermally equilibrated for at least thirty minutes prior to use. For the Perkin Elmer instrument, the scan range was 200-800 nm; the scan speed was 960 nm per minute; the slit width was 4 nm; the mode was set on transmission; and baseline correction was selected. Baseline correction was performed using cuvettes containing plastic two-piece lens holders and the same solvents. These two-  
 30 piece contact lens holders were designed to hold the sample in the quartz cuvette in the location through which the incident light beam traverses. The reference cuvette also contained a two-piece holder. To ensure that the thickness of the samples is constant, all lenses were made using identical molds. The center thickness of the contact lens was measured using an electronic thickness gauge. Reported center thickness and percent transmission spectra are obtained by averaging three individual lens data.

35 **[0196]** It is important to ensure that the outside surfaces of the cuvette are completely clean and dry and that no air bubbles are present in the cuvette. Repeatability of the measurement is improved when the reference cuvette and its lens holder remain constant and when all samples use the same sample cuvette and its lens holder, making sure that both cuvettes are properly inserted into the instrument.

40 **EXAMPLES**

**[0197]** The following abbreviations will be used throughout the Examples and Figures and have the following meanings: The following abbreviations will be used throughout the Preparations and Examples and have the following meanings:

45 BC: back curve plastic mold  
 FC: front curve plastic mold  
 Da: dalton or g/mole  
 kDa: kilodalton or an atomic mass unit equal to 1,000 daltons  
 mL: milliliter  
 50 L: liter  
 g: gram or grams  
 mg: milligram or milligrams  
 mmol: millimoles  
 eq: equivalent or equivalents  
 55 M: molar concentration  
 N: normal concentration  
 mM: millimolar concentration  
 DMA: N, N-dimethylacrylamide (Jarchem)

HEMA: 2-hydroxyethyl methacrylate (Bimax)  
 PVP: poly(N-vinylpyrrolidone) (ISP Ashland)  
 TEGDMA: tetraethylene glycol dimethacrylate (Esstech)  
 Irgacure 184: 1-hydroxy-cyclohexyl-phenyl ketone  
 5 Irgacure 819: bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide (BASF or Ciba Specialty Chemicals)  
 Irgacure 1870: blend of bis(2,6-dimethoxybenzoyl)-2,4,4-trimethyl-pentylphosphineoxide and 1-hydroxy-cyclohexyl-phenyl-ketone (BASF or Ciba Specialty Chemicals)  
 mPDMS: mono-n-butyl terminated monomethacryloxypropyl terminated polydimethylsiloxane ( $M_n = 800-1000$  daltons) (Gelest)  
 10 HO-mPDMS: mono-n-butyl terminated mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated polydimethylsiloxane ( $M_n = 400-1500$  daltons) (Ortec or DSM-Polymer Technology Group)  
 SiMAA: 2-propenoic acid, 2-methyl-2-hydroxy-3-[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propoxy]propyl ester (Toray) or 3-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)-2-hydroxypropyl methacrylate  
 D3O: 3,7-dimethyl-3-octanol (Vigon)  
 15 DI water: deionized water  
 MeOH: methanol  
 IPA: isopropyl alcohol  
 TFA: trifluoroacetic acid  
 E3NP: ethyl 3-nitropropionate  
 20 TEA: trimethylamine  
 tBuOH: tert-butanol  
 DPPA: diphenylphosphoryl azide  
 MHPP: methyl 3-(4-hydroxyphenyl)propanoate  
 EDC: ethyl dimethylaminopropyl carbodiimide hydrochloride  
 25 DIPCDI: diisopropyl carbodiimide  
 DMAP: N,N-dimethylaminopyridine  
 B<sub>2</sub>(pin)<sub>2</sub>: bis(pinacolato)diboron  
 Norbloc: 2-(2'-hydroxy-5-methacryloxyethylphenyl)-2H-benzotriazole (Janssen)  
 PP: polypropylene which is the homopolymer of propylene  
 30 TT: Tuftec which is a hydrogenated styrene butadiene block copolymer (Asahi Kasei Chemicals) Z: Zeonor which is a polycycloolefin thermoplastic polymer (Nippon Zeon Co Ltd)  
 TL03 lights: Phillips TLK 40W/03 bulbs  
 Borate Buffered Packing Solution: 18.52 grams (300 mmol) of boric acid, 3.7 grams (9.7 mmol) of sodium borate decahydrate, and 28 grams (197 mmol) of sodium sulfate were dissolved in enough deionized water to fill a 2 liter volumetric flask.  
 35

## EXAMPLES


### Example 1 - Synthesis of Compound (H) as shown in Scheme 1

40 **[0198]**

45

50

55



Methyl 2-(3-(*tert*-butyl)-4-hydroxyphenyl)acetate (A):

**[0199]** A mixture of methyl 2-(4-hydroxyphenyl)acetate (49.85 g, 300 mmol), *tert-butyl* alcohol (66.71 g, 900 mmol, 3 eq.) and phosphoric acid crystals (88.2 g, 900 mmol, 3 eq.) was heated at 75 to 80°C for one day. After cooling to room temperature, the mixture was diluted with dichloromethane (500 mL), washed sequentially with water (200 mL), saturated sodium bicarbonate (3 x 200 mL), and saturated brine (200 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Biotage-75 column eluting with a gradient of 50 to 100% dichloromethane in heptanes, to give compound (A) (47.9 g, 72%) as a pale-yellow oil.

Methyl 2-(3-bromo-5-(*tert*-butyl)-4-hydroxyphenyl)acetate (B):

**[0200]** Bromine (34.44 g, 215.49 mmol) was added dropwise to a solution of compound (A) (47.9 g, 215 mmol, 1 eq.) in methanol (1 L) at 5-10°C. The mixture was stirred at room temperature for 30 minutes. Water (100 mL) was added to quench the reaction and the mixture was concentrated under reduced pressure to remove volatiles. The residue was diluted with ethyl acetate (800 mL), washed with water (200 mL) and saturated brine (200 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give compound (B) (60.8 g, 94%) as a pale-yellow oil.

Methyl 2-(3-bromo-5-(*tert*-butyl)-4-(methoxymethoxy)phenyl)acetate (C):

**[0201]** Triethylamine (27.9 mL, 200 mmol, 2 eq.) and DMAP (1.22 g, 10 mmol, 0.1 eq.) were added to a solution of compound (B) (30.1 g, 100 mmol) in dichloromethane (500 mL) at room temperature. The reaction was cooled to 0°C and chloromethyl methyl ether (11.4 mL, 150 mmol, 1.5 eq.) was added dropwise. The resulting mixture was slowly warmed to room temperature and stirred overnight. Water (200 mL) was added to quench the reaction and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an AnaLogix 65-220 g column, eluting with a gradient of 0 to 75% dichloromethane in heptanes, to give compound (C) (6.9

## EP 3 645 532 B9

g, 20%) as a pale-yellow oil. The unreacted starting material (**B**, 22.0 g) was recovered and reused to provide additional compound (**C**) (5.9 g, 23%) as a pale-yellow oil.

Methyl 2-(3-(*tert*-butyl)-4-(methoxymethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (**D**):

**[0202]** A mixture of compound (**C**) (11.77 g, 34.1 mmol), *bis*(pinacolato)diboron (9.52 g, 37.5 mmol, 1.1 eq.), potassium acetate (11.71 g, 119 mmol, 3.5 eq.) and 1,1'-*bis*(diphenylphosphino)-ferrocene (0.95 g, 1.70 mmol, 0.05 eq.) in 1,4-dioxane (230 mL) was sparged with nitrogen for 10 minutes. 1,1'-*bis*(Diphenylphosphino)-ferrocenedichloropalladium complex with dichloromethane (1.40 g, 1.70 mmol, 0.05 eq.) was added, and the mixture was sparged with nitrogen for an additional 10 minutes. The resulting mixture was refluxed overnight. After cooling to room temperature, the mixture was diluted with ethyl acetate (400 mL), washed with water (200 mL) and saturated brine (200 mL). The combined aqueous layers were extracted with ethyl acetate (2 x 200 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified over silica gel (500 g) eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound (**D**) (7.2 g, 54%) as a yellow-green oil.

1,10-Phenanthroline 1-oxide (**E-1**):

**[0203]** A 30% aqueous hydrogen peroxide solution (39 g, 344 mmol, 1.38 eq.) was added to a solution of 1,10-phenanthroline (**E-2**) (45.0 g, 250 mmol, 1 eq.) in acetic acid (300 mL) at room temperature. The resulting mixture was heated at 50-60°C overnight. The mixture was poured into ice-water (1.5 L) and basified with 6M sodium hydroxide (~700 mL) to pH 9. The mixture was extracted with dichloromethane (10 x 600 mL). The combined organic layers were dried over sodium sulfate and sodium bisulfite solids for one day, filtered, and concentrated under reduced pressure to give compound (**E-1**) (14 g) as a green solid. Liquid chromatography mass spectrometry (LCMS) indicated that the aqueous layer still contained a significant amount of the desired compound. The aqueous layer was concentrated under reduced pressure to a volume of ~500 mL. Dichloromethane (1 L) was added and the mixture was stirred for 10 minutes and filtered through celite. The celite cake was triturated in hot dichloromethane (4 x 1.5 L) for 30 minutes each time and filtered. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give additional compound (**E-1**) (11 g, 50% combined yield) as a yellow-green solid.

2-Bromo-1,10-phenanthroline (**E**):

**[0204]** A mixture of compound (**E-1**) (25 g, 127 mmol), tetrabutylammonium bromide (61.61 g, 191 mmol, 1.5 eq.), and 4 Å molecular sieves (125 g) in dichloromethane (3.5 L) was stirred at room temperature for 10 minutes. *p*-Toluenesulfonic anhydride (62.38 g, 191 mmol, 1.5 eq.) was added, and the mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate was concentrated under reduced pressure. Purification of the material to the desired levels required 6 separate chromatographic runs. The first two purifications were run on AnaLogix 65-330 g columns eluting each time with a gradient of 0 to 10% methanol in dichloromethane. The last four on AnaLogix 65-220 g columns eluting each time with a gradient of 0 to 5% methanol in dichloromethane to finally give compound (**E**) (15.9 g, 48% total yield) as a yellow solid.

2-(3-(*tert*-Butyl)-4-(methoxymethoxy)-5-(1,10-phenanthrolin-2-yl)phenyl)acetic acid (**F**):

**[0205]** A mixture of compound (**D**) (7.0 g, 17.8 mmol, 1.1 eq.), compound (**E**) (4.2 g, 16.2 mmol), and potassium phosphate tribasic monohydrate (11.2 g, 48.7 mmol, 3 eq.) in 1,4-dioxane (400 mL) and water (100 mL) was sparged with nitrogen for 15 minutes. Tetrakis-(triphenylphosphine)-palladium(O) (1.87 g, 1.622 mmol, 0.1 eq.) was added and the mixture was sparged with nitrogen for an additional 5 minutes. The resulting mixture was refluxed for 7 hours, at which time LCMS indicated that the reaction was complete. The mixture was cooled to room temperature and stirred overnight. The mixture was diluted with water (500 mL) and extracted with ethyl acetate (200 mL). LCMS analysis indicated that the organic layer contained a small amount of desired product, along with most of the impurities, while the aqueous layer contained mainly the desired product. The aqueous layer was acidified with 1M HCl to pH 5 and extracted with ethyl acetate (3 x 400 mL). These combined extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give compound (**F**) (3.5 g) as a yellow solid. The original organic layer was washed with saturated sodium bicarbonate (2 x 100 mL) to remove the product. The combined aqueous layers were acidified to pH 3 with 1M HCl, and extracted with ethyl acetate (3 x 200 mL). The combined extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give additional compound (**F**) (1.1 g, 69% total yield) as a yellow solid.

## EP 3 645 532 B9

2-(3-(*tert*-Butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetic acid hydrochloride (**G**):

**[0206]** 5M HCl in isopropanol (400 mL, 2 moles) was added to a solution of compound (**F**) (4.5 g, 10.45 mmol) in THF (200 mL) at room temperature. The mixture was heated at 50°C in an oil bath overnight. LCMS indicated that the reaction was about 50% complete. The mixture was concentrated under reduced pressure to a volume of ~100 mL. THF (100 mL) and 5M HCl in isopropanol (300 mL) were added. The mixture was heated at 50°C in an oil bath for 2 hours, at which time LCMS indicated that the reaction was complete. The mixture was concentrated under reduced pressure to a volume of ~50 mL. The resulting slurry was diluted with ethyl acetate (100 mL). The resulting solid was collected by filtration and washed with additional ethyl acetate (20 mL) to give compound (**G**) (2.7 g, 98.7% purity by HPLC) as a yellow solid. <sup>1</sup>H NMR (500 MHz, MeOD) δ 9.29 (dd, 1H), 9.22 (dd, 1H), 8.70 (d, 1H), 8.42 (d, 1H), 8.26 (m, 3H), 7.76 (s, 1H), 7.46 (s, 1H), 3.71 (s, 2H), 1.58 (s, 9H).

2-(2-(3-(*tert*-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethyl methacrylate (**H**):

**[0207]** Compound (**G**) (796 mg, ~ 1.89 mMol), and ethyl dimethylaminopropyl carbodiimide hydrochloride (570 mg, ~ 3 mMol) are stirred in 40 mL of methylene chloride at room temperature, under a nitrogen atmosphere. While continuously stirring the mixture, 2 g of 2-hydroxyethyl methacrylate (large excess) is added to the reaction mixture which is then stirred overnight at ambient temperature.

**[0208]** Once all of compound (**G**) has been consumed, volatiles are removed under reduced pressure. The residue (**H**) is dissolved in ethyl acetate and washed three times with deionized water prior to purification by flash chromatography using dichloromethane and ethyl acetate as the solvents. The <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.19 (dd, 1H), 8.15-8.30 (m, 3H), 7.78 (d, 1H), 7.73 (s, 2H), 7.60 (dd, 1H), 7.28 (d, 1H), 6.02 (m, 1H), 6.47 (m, 1H), 4.35 (m, 4H), 3.64 (s, 2H), 1.85 (m, 3H), 1.55 (s, 9H).

**[0209]** FIG. 1 shows the UV-VIS transmission spectra of Norbloc® and compound (**H**) in 0.2 mM methanol solutions. Compound (**H**) was more effective than Norbloc® at absorbing UV light in the range of 250-280 nm and exhibit bathochromic shifts of about 35 nm in comparison to Norbloc® in the range of 360-400 nm.

### Example 2. Silicone Hydrogel Formation

**[0210]** A 10 gram batch of a reactive monomer mixture was prepared composed of 77 weight percent of the formulation listed in Table 5 and 23 weight percent of the diluent D3O. All of the components were mixed in a jar under a nitrogen atmosphere at room temperature for 68 hours (over the weekend). The reactive monomer mixture was then filtered through a 3 μm filter using a stainless steel syringe under pressure.

TABLE 5

Component	Base Formulation (weight %)
mPDMS 1000	30.93
SiMAA	27.94
DMA	23.94
HEMA	5.99
TEGDMA	1.50
PVP K90	7.00
Irgacure 1870	0.68
Compound ( <b>H</b> )	2.00
Σ Components	100

**[0211]** The filtered reactive monomer mixture was degassed at ambient temperature by applying vacuum (about 40 torr) for about 45 minutes. Then, in a glove box with a nitrogen gas atmosphere and about 0.0-0.1 percent oxygen gas, about 75-100 μL of the reactive mixture were dosed using an Eppendorf pipet at room temperature into the FC made of 90:10 Z:TT. The BC made of 90:10 Z:TT was then placed onto the FC. The molds were equilibrated for a minimum of twelve hours in the glove box prior to dosing. Trays containing eight mold assemblies each were transferred into an adjacent glove box maintained at 65°C, and the lenses were cured from the top and the bottom for 10 minutes using 435 nm LED lights having an intensity of about 5.0 mW/cm<sup>2</sup> at the tray's location. The LED light sources were about


11.5 inches away from the trays.

**[0212]** The lenses were manually de-molded with most lenses adhering to the FC and released by suspending the lenses in about one liter of 70 percent IPA for about one or two hours, followed by washing two times with 70 percent IPA and then three times with DI water. Each washing step lasted about 30 minutes. The lenses were equilibrated in borate buffered packaging solution overnight and then stored in fresh borate buffered packaging solution thereafter. A person of ordinary skill recognizes that the exact lens release process can be varied depending on the lens formulation and mold materials, regarding the concentrations of the aqueous isopropanol solutions, the number of washings with each solvent, and the duration of each step. The purpose of the lens release process is to release all of the lenses without defects and transition from diluent swollen networks to the packaging solution swollen hydrogels. Lenses were made using an astigmatic optical design and had an average center thickness of 81.7 microns (Example 2A). Other lenses were made using a spherical optical design and had an average center thickness of 73.0 microns (Example 2B).

**[0213]** FIG. 2 shows the UV-VIS spectra of the lenses containing compound (H). Compound (H) was an effective UV light blocker up to about 380 nm at which point absorption of light began to diminish and transmission increased markedly to about 90% at wavelengths higher than about 450 nm. The astigmatic lenses were slightly more bathochromatically shifted than the spherical lenses because of the difference in average thickness.

### Claims

1. A compound of formula I:



Formula I

wherein:

$R^1$  at each occurrence is independently H, halo,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl, aryl, or aryl- $C_1$ - $C_6$ -alkyl; at least one  $R^2$  is a group of formula  $R_g$ -L, wherein  $R_g$  is a polymerizable group and L is a linking group, and the remaining  $R^2$  are independently at each occurrence  $R_g$ -L, H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl, aryl, or aryl- $C_1$ - $C_6$ -alkyl, wherein each alkyl, cycloalkyl, and aryl group is unsubstituted or substituted, wherein  $R_g$  is styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinylamide, (meth)acrylate, or (meth)acrylamide, and wherein the linking group is  $C_1$ - $C_8$  alkylene,  $C_1$ - $C_8$  oxaalkylene,  $C_1$ - $C_8$  thiaalkylene,  $C_1$ - $C_8$  alkylene-carboxylate- $C_1$ - $C_8$  alkylene,  $C_1$ - $C_8$  alkylene-amide- $C_1$ - $C_8$  alkylene, or  $C_1$ - $C_8$  alkylene-amine- $C_1$ - $C_8$  alkylene.

2. The compound of claim 1 wherein  $R^1$  is at each occurrence is independently H or halo.

3. The compound of any one of claims 1 to 2 wherein one  $R^2$  is H and remaining  $R^2$  are independently H,  $C_1$ - $C_6$  alkyl, or  $R_g$ -L.

4. The compound of any one of claims 1 to 3 wherein  $R_g$  is (meth)acrylate or (meth)acrylamide.

5. The compound of any one of claims 1 to 4 wherein the linking group is selected from  $C_1$ - $C_8$  alkylene, preferably  $C_2$ - $C_6$  alkylene, and  $C_1$ - $C_8$  oxaalkylene, preferably  $C_2$ - $C_6$  oxaalkylene, each of which is optionally substituted with 1 or 2 groups independently selected from hydroxyl and siloxy.


6. The compound of claim 1 that is selected from: 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)ac-

etoxy)ethyl methacrylate; 2-(2-(4-hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetoxo)ethyl methacrylate; 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethyl methacrylate; and 2-(2-(4-hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethyl methacrylate.

- 5 7. An ophthalmic device comprising a free radical reaction product of the compound of any one of claims 1 to 6 and one or more monomers suitable for making the ophthalmic device.
8. The ophthalmic device of claim 7 wherein the monomer suitable for making the ophthalmic device comprises a hydrophilic monomer, a silicone-containing component, or mixtures thereof.
- 10 9. The ophthalmic device of any one of claims 7 to 8 that is a contact lens, a corneal onlay, a corneal inlay, an intraocular lens, or an overlay lens.
10. A hydrogel formed from a reactive mixture comprising: the compound of any one of claims 1 to 6; and one or more monomers suitable for making the hydrogel.
- 15 11. The hydrogel of claim 10 wherein the monomer suitable for making the hydrogel comprises a hydrophilic monomer, a silicone-containing component, or mixtures thereof.
12. The hydrogel of any one of claims 10 to 11 wherein the monomer suitable for making the hydrogel comprises a hydrophilic monomer and a silicone-containing component.
13. A contact lens comprising the hydrogel of any one of claims 10 to 12.
14. A method for making an ophthalmic device, the method comprising:
- 25 (a) providing a reactive mixture containing the compound of any one of claims 1 to 6, one or more monomers, and a radical initiator; and
- (b) polymerizing the reactive mixture to form the ophthalmic device.
- 30 15. A compound that is 2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetic acid or salt thereof.

35 **Patentansprüche**

1. Verwendung der Formel I:



Formel I

50 wobei:

R<sup>1</sup> bei jedem Vorkommen unabhängig für H, Halogen, C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>3</sub>-C<sub>12</sub>-Cycloalkyl, Aryl oder Aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl steht;

55 mindestens ein R<sup>2</sup> für eine Gruppe der Formel R<sub>g</sub>-L steht, wobei R<sub>g</sub> für eine polymerisierbare Gruppe steht und L für eine Verknüpfungsgruppe steht, und die übrigen R<sup>2</sup> unabhängig bei jedem Vorkommen für R<sub>g</sub>-L, H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>3</sub>-C<sub>12</sub>-Cycloalkyl, Aryl oder Aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl stehen,

## EP 3 645 532 B9


wobei jede Alkyl-, Cycloalkyl- und Arylgruppe unsubstituiert oder substituiert ist,  
wobei  $R_g$  für Styryl, Vinylcarbonat, Vinylether, Vinylcarbamat, N-Vinylactam, N-Vinylamid, (Meth)-acrylat oder (Meth)acrylamid steht und

wobei die Verknüpfungsgruppe für  $C_1-C_8$ -Alkylen,  $C_1-C_8$ -Oxaalkylen,  $C_1-C_8$ -Thiaalkylen,  $C_1-C_8$ -Alkylen-carboxylat- $C_1-C_8$ -alkylen,  $C_1-C_8$ -Alkylenamid- $C_1-C_8$ -alkylen oder  $C_1-C_8$ -Alkylenamin- $C_1-C_8$ -alkylen steht.

- 5 2. Verbindung nach Anspruch 1, wobei  $R^1$  bei jedem Vorkommen unabhängig für H oder Halogen steht.
- 10 3. Verbindung nach einem der Ansprüche 1 bis 2, wobei ein  $R^2$  für H steht und die übrigen  $R^2$  unabhängig bei jedem Vorkommen für H,  $C_1-C_6$ -Alkyl oder  $R_g-L$  stehen.
- 15 4. Verbindung nach einem der Ansprüche 1 bis 3, wobei  $R_g$  für (Meth)acrylat oder (Meth)acrylamid steht.
- 20 5. Verbindung nach einem der Ansprüche 1 bis 4, wobei die Verknüpfungsgruppe aus  $C_1-C_8$ -Alkylen, vorzugsweise  $C_2-C_6$ -Alkylen, und  $C_1-C_8$ -Oxaalkylen, vorzugsweise  $C_2-C_6$ -Oxaalkylen, ausgewählt ist, wobei jede dieser Gruppen gegebenenfalls durch 1 oder 2 Gruppen, die unabhängig aus Hydroxyl und Siloxy ausgewählt sind, substituiert sein kann.
- 25 6. Verbindung nach Anspruch 1, die aus 2-(2-(3-(tert-Butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)-phenyl)acetoxy)ethylmethacrylat; 2-(2-(4-Hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethylmethacrylat; 2-(2-(3-(tert-Butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethylmethacrylat und 2-(2-(4-Hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethylmethacrylat ausgewählt ist.
- 30 7. Ophthalmische Vorrichtung, umfassend ein Radikalreaktionsprodukt der Verbindung nach einem der Ansprüche 1 bis 6 und eines oder mehrerer Monomere, die zur Herstellung der ophthalmischen Vorrichtung geeignet sind.
- 35 8. Ophthalmische Vorrichtung nach Anspruch 7, wobei das Monomer, das zur Herstellung der ophthalmischen Vorrichtung geeignet ist, ein hydrophiles Monomer, eine silikonhaltige Komponente oder Mischungen davon umfasst.
- 40 9. Ophthalmische Vorrichtung nach einem der Ansprüche 7 bis 8, bei der es sich um eine Kontaktlinse, ein Hornhaut-Onlay, ein Hornhaut-Inlay, eine Intraokularlinse oder eine Overlay-Linse handelt.
- 45 10. Hydrogel, gebildet aus einer reaktiven Mischung, umfassend: die Verbindung nach einem der Ansprüche 1 bis 6 und ein oder mehrere Monomere, die zur Herstellung des Hydrogels geeignet sind.
- 50 11. Hydrogel nach Anspruch 10, wobei das Monomer, das zur Herstellung des Hydrogels geeignet ist, ein hydrophiles Monomer, eine silikonhaltige Komponente oder Mischungen davon umfasst.
- 55 12. Hydrogel nach einem der Ansprüche 10 bis 11, wobei das Monomer, das zur Herstellung des Hydrogels geeignet ist, ein hydrophiles Monomer und eine silikonhaltige Komponente oder Mischungen davon umfasst.
13. Kontaktlinse, umfassend das Hydrogel nach einem der Ansprüche 10 bis 12.
14. Verfahren zur Herstellung einer ophthalmischen Vorrichtung, wobei das Verfahren Folgendes umfasst:
  - (a) Bereitstellen einer reaktiven Mischung, die die Verbindung nach einem der Ansprüche 1 bis 6, ein oder mehrere Monomere und einen Radikalinitiator umfasst; und
  - (b) Polymerisieren der reaktiven Mischung zur Bildung der ophthalmischen Vorrichtung.
15. Verbindung, bei der es sich um 2-(3-(tert-Butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)essigsäure oder ein Salz davon handelt.

### Revendications

1. Composé de formule I :



formule I

R<sup>1</sup> étant en chaque occurrence indépendamment H, halogéno, C<sub>1-6</sub> alkyle, C<sub>3-12</sub> cycloalkyle, aryle ou aryl-C<sub>1-6</sub> alkyle ;  
 au moins un R<sup>2</sup> étant un groupe de formule R<sub>g</sub>-L, R<sub>g</sub> étant un groupe polymérisable et L étant un groupe de liaison, et les R<sup>2</sup> restants étant indépendamment en chaque occurrence R<sub>g</sub>-L, H, C<sub>1-6</sub> alkyle, C<sub>3-12</sub> cycloalkyle, aryle ou aryl-C<sub>1-6</sub> alkyle,  
 chaque groupe alkyle, cycloalkyle et aryle étant non substitué ou substitué,  
 R<sub>g</sub> étant styryle, vinylcarbonate, vinyléther, vinylcarbamate, N-vinylactame, N-vinylamide, (méth)acrylate ou (méth)acrylamide, et  
 le groupe de liaison étant C<sub>1-8</sub> alkylène, C<sub>1-8</sub> oxaalkylène, C<sub>1-8</sub> thiaalkylène, C<sub>1-8</sub> alkylène-carboxylate-C<sub>1-8</sub> alkylène, C<sub>1-8</sub> alkylène-amide-C<sub>1-8</sub> alkylène ou C<sub>1-8</sub> alkylène-amine-C<sub>1-8</sub> alkylène.

2. Composé selon la revendication 1, R<sup>1</sup> étant en chaque occurrence indépendamment H ou halogéno.
3. Composé selon l'une quelconque des revendications 1 à 2, un R<sup>2</sup> étant H et les R<sup>2</sup> restants étant indépendamment H, C<sub>1-6</sub> alkyle ou R<sub>g</sub>-L.
4. Composé selon l'une quelconque des revendications 1 à 3, R<sub>g</sub> étant (méth)acrylate ou (méth)acrylamide.
5. Composé selon l'une quelconque des revendications 1 à 4, le groupe de liaison étant choisi parmi C<sub>1-8</sub> alkylène, préférablement C<sub>2-6</sub> alkylène, et C<sub>1-8</sub> oxaalkylène, préférablement C<sub>2-6</sub> oxaalkylène, chacun desquels étant éventuellement substitué par 1 ou 2 groupes indépendamment choisis parmi hydroxyle et siloxy.
6. Composé selon la revendication 1 qui est choisi parmi le méthacrylate de 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phénanthroline-2-yl)phényl)acétoxy)éthyle ; le méthacrylate de 2-(2-(4-hydroxy-3-(1,10-phénanthroline-2-yl)phényl)acétoxy)éthyle ; le méthacrylate de 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phénanthroline-2-yl)phényl)acétamido)éthyle ; et le méthacrylate de 2-(2-(4-hydroxy-3-(1,10-phénanthroline-2-yl)phényl)acétamido)éthyle.
7. Dispositif ophtalmique comprenant un produit de réaction avec des radicaux libres du composé selon l'une quelconque des revendications 1 à 6 et un ou plusieurs monomères appropriés pour préparer le dispositif ophtalmique.
8. Dispositif ophtalmique selon la revendication 7, le monomère approprié pour la préparation du dispositif ophtalmique comprenant un monomère hydrophile, un composant contenant une silicone ou des mélanges correspondants.
9. Dispositif ophtalmique selon l'une quelconque des revendications 7 à 8 qui est une lentille de contact, une incrustation cornéenne, un insert cornéen, une lentille intraoculaire ou une lentille à revêtement.
10. Hydrogel formé à partir d'un mélange réactif comprenant : le composé selon l'une quelconque des revendications 1 à 6 ; et un ou plusieurs monomères appropriés pour préparer l'hydrogel.
11. Hydrogel selon la revendication 10, le monomère approprié pour préparer l'hydrogel comprenant un monomère hydrophile, un composant contenant une silicone ou des mélanges correspondants.
12. Hydrogel selon l'une quelconque des revendications 10 à 11, le monomère approprié pour la préparation de l'hydrogel

comprenant un monomère hydrophile et un composant contenant une silicone.

**13.** Lentille de contact comprenant l'hydrogel selon l'une quelconque des revendications 10 à 12.

5 **14.** Procédé pour la préparation d'un dispositif ophtalmique, le procédé comprenant :

(a) la mise à disposition d'un mélange réactif contenant le composé selon l'une quelconque des revendications 1 à 6, un ou plusieurs monomères, et un initiateur de radicaux ; et

10 (b) la polymérisation du mélange réactif pour former le dispositif ophtalmique.

**15.** Composé qui est l'acide 2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phénanthroline-2-yl)phényl)acétique ou un sel correspondant.

15

20

25

30

35

40

45

50

55




FIG. 1 – Transmission Spectra of 0.2 mM solutions of Norbloc® and Compound (H) in methanol




Fig. 2 - Transmission Spectra of Contact Lenses made in Examples 2A and 2B using Compound (H) in the reactive monomer mixture. Example 2A used an astigmatic optical design while Example 2B used a spherical optical design.

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 2017073467 A1 [0005]
- EP 2123638 A1 [0006]
- US 2010168359 A1 [0011]
- US 3808178 A [0038]
- US 4120570 A [0038]
- US 4136250 A [0038]
- US 4153641 A [0038]
- US 4740533 A [0038]
- US 5034461 A [0038]
- US 5070215 A [0038] [0090]
- US 5244981 A [0038] [0047]
- US 5314960 A [0038] [0047]
- US 5331067 A [0038] [0047]
- US 5371147 A [0038] [0047]
- US 5760100 A [0038] [0047]
- US 5849811 A [0038] [0047]
- US 5962548 A [0038]
- US 5965631 A [0038] [0047]
- US 5998498 A [0038] [0047]
- US 6367929 B [0038] [0047]
- US 6822016 B [0038] [0047]
- US 6943203 B [0038] [0047]
- US 6951894 B [0038]
- US 7052131 B [0038]
- US 7247692 B [0038] [0047]
- US 7396890 B [0038]
- US 7461937 B [0038]
- US 7468398 B [0038]
- US 7538146 B [0038]
- US 7553880 B [0038] [0047]
- US 7572841 B [0038]
- US 7666921 B [0038] [0047]
- US 7691916 B [0038]
- US 7786185 B [0038] [0047]
- US 7825170 B [0038]
- US 7915323 B [0038]
- US 7994356 B [0038]
- US 8022158 B [0038] [0047]
- US 8163206 B [0038]
- US 8273802 B [0038] [0047]
- US 8399538 B [0038] [0047]
- US 8415404 B [0038]
- US 8420711 B [0038]
- US 8450387 B [0038] [0047]
- US 8487058 B [0038] [0047]
- US 8568626 B [0038]
- US 8937110 B [0038] [0047]
- US 8937111 B [0038] [0047]
- US 8940812 B [0038] [0047]
- US 8980972 B [0038]
- US 9056878 B [0038] [0047]
- US 9125808 B [0038] [0047]
- US 9140825 B [0038] [0047]
- US 9156934 B [0038] [0047]
- US 9170349 B [0038] [0047]
- US 9217813 B [0038]
- US 9244196 B [0038] [0047]
- US 9244197 B [0038] [0047]
- US 9260544 B [0038] [0047]
- US 9297928 B [0038] [0047]
- US 9297929 B [0038] [0047]
- EP 080539 A [0038]
- US 4436887 A [0046]
- US 4495313 A [0046]
- US 4889664 A [0046]
- US 5006622 A [0046]
- US 5039459 A [0046]
- US 5236969 A [0046]
- US 5270418 A [0046]
- US 5298533 A [0046]
- US 5824719 A [0046]
- US 6420453 B [0046]
- US 6423761 B [0046]
- US 6767979 B [0046]
- US 7934830 B [0046]
- US 8138290 B [0046]
- US 8389597 B [0046]
- US 4659782 A [0047]
- US 4659783 A [0047]
- US 6087415 A [0047]
- US 5776999 A [0047]
- US 5789461 A [0047]
- US 6867245 B [0047]
- US 7249848 B [0047]
- US 7956131 B [0047]
- US 8470906 B [0047]
- US 8507577 B [0047]
- US 8637621 B [0047]
- US 8703891 B [0047]
- US 9057821 B [0047]
- WO 0322321 A [0047]
- WO 2008061992 A [0047]
- US 20100048847 A [0047]
- US 4910277 A [0090]
- WO 03022321 A [0169]
- US 6020445 A [0169]
- US 3408429 A [0185]
- US 3660545 A [0185]

## EP 3 645 532 B9

- US 4113224 A [0185]
- US 4197266 A [0185]
- US 20180037690 A [0192]

### Non-patent literature cited in the description

- Statement on Ocular Ultraviolet Radiation Hazards in Sunlight. American Optometric Association, 10 November 1993 [0002]
- **DOUTCH, J.J. ; QUANTOCK, A.J. ; JOYCE, N.C. ; MEEK, K.M.** *Biophys. J.*, 2012, vol. 102, 1258-1264 [0002]
- **HAM, W.T ; MUELLER, H. A. ; SLINEY, D. H.** *Nature*, 1976, vol. 260 (5547), 153-5 [0003]
- **LISA M.** Enantiopure Chiral Concave 1,10-Phenanthrolines. *European Journal of Organic Chemistry*, 2016, vol. 2016 (6) [0007]
- Synthesis of Dinucleating Phenanthroline-Based Ligands. **LAM F.** *Tetrahedron*. Elsevier Science Publishers, vol. 55 [0008]
- Synthesis, Electrochemical And Spectroscopic Properties Of Pendant Hydroquinone- And Quinone-Substituted Polypyridyl Ruthenium(II) Complexes. **BERTHON R A.** *Inorganica Chimica Acta*. Elsevier BV, 1993, vol. 204 [0009]
- Concave reagents. 5. Bimacrocyclic 1,10-phenanthroline cyclophanes. **LUENING ULRICH et al.** *Chemische Beri. VCH*, 1990, vol. 123 [0010]
- Compendium of Polymer Terminology and Nomenclature. IUPAC Recommendations 2008 [0020]
- *CHEMICAL ABSTRACTS*, #148969-96-4 [0157]
- *CHEMICAL ABSTRACTS*, 79704-35-1 [0157]
- *CHEMICAL ABSTRACTS*, 80293-60-3 [0157]
- *CHEMICAL ABSTRACTS*, 163674-35-9 [0157]
- **J. V. CRIVELLO ; K. DIETLIKER.** Photoinitiators for Free Radical Cationic & Anionic Photopolymerization. John Wiley and Sons, 1998, vol. III [0173]